



 Λ

2 Soi Soonvijai 7, New Petchburi Rd., Bangkok 10310 Tel. 0-2310-3000 Fax 0-2318-1546 www.bangkokhospital.com, www.wattanosoth.com



Wattanosoth Cancer Registry 2013

Table of **CONTENTS**



.79

| Message from CEO | 1 |
|--|------------|
| Message from Director | 2 |
| Cancer Registry 2013 : Abstract | 3 |
| Annual Cancer Registry 2013 | 4 |
| Distribution of All Cancer by Age and Gender, The Top 10 Lead | ding |
| Site of Cancer, Patient Category, Method of Diagnosis, Staging | <i>g</i> , |
| Type of Treatment, Patient Follow up, Patient Nationality | |
| Review of Breast Cancer | |
| Review of Lung Cancer | |
| Review of Colorectal Cancer | |
| Review of Prostate gland Cancer | |
| Review of Hepatobiliary Cancer | |
| Hematologic Malignancies 2013 | |
| Age Distribution in All Male Cancer Number of Case | |
| Age Distribution in All Female Cancer Number of Case | |
| Breast Cancer Survival | 71 |
| Colorectal Cancer Survival | |
| Lung Cancer Survival | |





Cancer is a paramount importance disease causes serious illness and suffering for both patient and family. It is one of a leading cause of death for decades. Beside there is still a lot more to learn and develop in order to fight this danger disease.

Wattanosoth Cancer Registry 2013 was established by Wattanosoth Hospital. It is a systematic collection of data gathering from patient during treatment and care process. The data is presented and used as an educational resource, sharing and utilizing of knowledge and experiences for multidisciplinary team. It is aim at the improvement of cancer therapy; the advantage for all every patients suffered from cancer and ultimately hopes to be the lights for them.

tomen

Krittavith Lertutsahakul, M.D. Chief Executive Officer – Group 1

Cancer Registry Team.

Message from **CEO**



Message from **Director**



The Cancer Registry of Bangkok Hospital – Soonvijai (BHS) has been published annually for 7 years and now it comes to the 8th edition.

The Cancer Registry has been adjusted to be up to date regularly and we notice that foreign patient is increasing continuously. Therefore, there is Top 10 Countries of foreign patients in this edition, in order to be information for a suitable treatment plan including to enhance the medical services to be the best for our patients.

The Cancer Registry is the important information which lead us to be an excellent cancer center and can be a benchmark to the international cancer institute, especially for MD Anderson Cancer Center, where we are a sister institute.

On behalf of Wattanosoth Hospital management, we are appreciated for the all the efforts and cooperation of the production team to be success on *The Cancer Registry 2013.*

Thiravud Khuhaprema, M.D., FRCST., FICS., Visiting Professor Hospital Director, Wattanosoth Cancer Hospital Bangkok Medical Services Center

Cancer Registry 2013 : Abstract

The total of new cases diagnosed as a malignancy at Bangkok Hospital – Soonvijai (BHS) is 1914 cases (excluding the hematologic malignancy). There was a 3 percent increase in the total number as compared to 1854 cases in 2012.

The sex ratio is 1:1. This age distribution has not changed since the year 2011. Patients who are between 50-69 y/o are the majority accounting for more than half of the total. The average age in male patients is 65-69 y/o which is slightly older than the female age of 55-59 y/o.

Top 5 malignancies are:1) Breast (Including in situ) - 23.20 percent2) I3) Colorectal - 10.87 percent4) I5) Liver and Hepatobiliary - 7.16 percent

The trend for the top 5 malignancies has not changed over the past 7 years (2006-2012). For the past 7 years the top 5 have been: Breast, Colorectal, Lung and Liver, and Prostate cancer. However, when compared to last year, the overall number of cases in Breast cancer increased significantly by 3.8 percent, Lung cancer increased by 4.0 percent, Colorectal cancer decreased by 6.2 percent, Prostate gland cancer increased by 6.4 percent and Liver and Hepatobiliary decreased by 10.2 percent.

The results of overall staging of patients who received treatment at Bangkok Hospital – Soonvijai (BHS) are: Stage I is 24.36 percent, Stage II is 20.19 percent, Stage III is 22.09 percent, and Stage IV is 22.84 percent. Unspecified stage (due to lack of pertinent information) is 6.35 percent. All results are similar to 2012 staging results.

Analysis of the primary treatments modalities indicates that surgery continues to be the majority (24 percent), followed by Radiation therapy (15 percent), Chemotherapy and Concurrent chemo-radiation (4 percent). Intervention treatment and Brachytherapy remained at 3 percent.

Patients with a cancer diagnosis decide to receive treatment at Wattanosoth Cancer Hospital at 22 percent equal to last year. and 9 percent (10 percent in 2012) of cancer patients decide to have primary treatment in other hospitals. Patients who came from other hospitals for a second opinion at BMC significantly increased to 36 percent (35 percent in 2012), however, those who decided to receive treatment at BMC equal to the year 2012 is 55 percent.

Patients who are still living after diagnosis or treatment in 2012 is 37 percent, patients alive without disease are 21 percent, and patients who have died with cancer as the cause are 2 percent. At this time no patients receiving treatment have been lost to follow-up.

Ratio of Thai to non-Thai patients is 3:2 in year 2013 equal to the year 2012. The top 5 rankings of non-Thai patients are: Myanmar, Bangladesh, United Arab Emirates, Oman and Kuwait, respectively.

The Top 5 malignancies of non-Thai patients are:1) Breast (Including in situ) - 20.42 percent2) Cold3) Lung - 9.74 percent4) Pros5) Liver and Hepatobiliary - 9.40 percent

It is the third time BHS can follow the patients for 5 years and report the 5-years survival. We have shown and discussed the data of those survivors of top 3 cancers which are breast, colorectal and lung in separated chapters.

2) Lung -11.55 percent
 4) Prostate gland - 7.31 percent

2) Colorectal - 10.44 percent
 4) Prostate gland - 9.51 percent




WATTANOSOTH ANNUAL CANCER REGISTRY 2013 **DISTRIBUTION OF ALL CANCER BY AGE AND GENDER**

| Ano | Ма | le | Fen | nale | Total | | |
|---------|--------|---------|--------|---------|--------|---------|--|
| Age | Number | Percent | Number | Percent | Number | Percent | |
| 00 - 04 | 0 | 0.00 | 1 | 0.10 | 1 | 0.05 | |
| 05 - 09 | 1 | 0.12 | 2 | 0.19 | 3 | 0.16 | |
| 10 - 14 | 2 | 0.23 | 1 | 0.10 | 3 | 0.16 | |
| 15 - 19 | 3 | 0.35 | 3 | 0.29 | 6 | 0.31 | |
| 20 - 24 | 4 | 0.46 | 7 | 0.67 | 11 | 0.57 | |
| 25 - 29 | 4 | 0.46 | 14 | 1.34 | 18 | 0.94 | |
| 30 - 34 | 13 | 1.50 | 24 | 2.29 | 37 | 1.93 | |
| 35 - 39 | 32 | 3.70 | 66 | 6.30 | 98 | 5.12 | |
| 40 - 44 | 38 | 4.39 | 109 | 10.40 | 147 | 7.68 | |
| 45 - 49 | 67 | 7.74 | 122 | 11.64 | 189 | 9.87 | |
| 50 - 54 | 91 | 10.51 | 137 | 13.07 | 228 | 11.91 | |
| 55 - 59 | 105 | 12.12 | 139 | 13.26 | 244 | 12.75 | |
| 60 - 64 | 122 | 14.09 | 125 | 11.93 | 247 | 12.90 | |
| 65 - 69 | 143 | 16.51 | 116 | 11.07 | 259 | 13.53 | |
| 70 - 74 | 108 | 12.47 | 70 | 6.68 | 178 | 9.30 | |
| 75 - 79 | 84 | 9.70 | 56 | 5.34 | 140 | 7.31 | |
| 80 - 84 | 31 | 3.58 | 29 | 2.77 | 60 | 3.13 | |
| 85 - 89 | 12 | 1.39 | 18 | 1.72 | 30 | 1.57 | |
| 90 - 94 | 4 | 0.46 | 7 | 0.67 | 11 | 0.57 | |
| 95 + | 2 | 0.23 | 2 | 0.19 | 4 | 0.21 | |
| Total | 866 | 100.00 | 1,048 | 100.00 | 1,914 | 100.00 | |

2012


■ Male ■ Female



THE TOP 10 LEADING SITE OF CANCER **IN BANGKOK HOSPITAL - SOONVIJAI**


| Code | Drimory oito | Male | | Fen | nale | Total | |
|---------|----------------------------|--------|---------|--------|---------|--------|---------|
| Code | Primary site | Number | Percent | Number | Percent | Number | Percent |
| C50/D05 | Breast (including in situ) | 1 | 0.12 | 443 | 42.27 | 444 | 23.20 |
| C33-C34 | Lung | 141 | 16.28 | 80 | 7.63 | 221 | 11.55 |
| C18-C20 | Colorectal | 113 | 13.05 | 95 | 9.06 | 208 | 10.87 |
| C61 | Prostate gland | 140 | 16.17 | 0 | 0.00 | 140 | 7.31 |
| C22-C24 | Liver & Hepatobiliary | 103 | 11.89 | 34 | 3.24 | 137 | 7.16 |
| C00-C14 | Head & Neck | 82 | 9.47 | 39 | 3.72 | 121 | 6.32 |
| C53 | Cervix | 0 | 0.00 | 92 | 8.78 | 92 | 4.81 |
| C73 | Thyroid gland | 17 | 1.96 | 65 | 6.20 | 82 | 4.28 |
| C44 | Skin | 30 | 3.46 | 20 | 1.91 | 50 | 2.61 |
| C67 | Bladder | 36 | 4.16 | 13 | 1.24 | 49 | 2.56 |

TOP 10 CANCER FOR ALL GENDER




OVERALL CANCER

TOP 10 CANCER IN MALE




TOP 10 CANCER IN FEMALE



Dx(Other)Rx(Other)Before **19%** Dx(Other)Rx(Other) 2nd Opinion only 36%

Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging) Rx = TreatmentHere = Within Bangkok Hospital - Soonvijai Other = Outside Bangkok Hospital - Soonvijai


METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)




Other = Previously diagnosed as Cancer from other Hospital but no documentation of diagnosis

6


PATIENT CATEGORY OF ALL CANCER **IN BANGKOK HOSPITAL - SOONVIJAI**




STAGING (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)



Stage 0 = Carcinoma in situ Non stage = In case of CA Brain Unspecified stage = Incomplete staging due to insufficient patient information



Female



| | Ma | ale | Fen | nale | Total | |
|-------------------------------------|--------|---------|--------|---------|--------|---------|
| Management of treatment | Number | Percent | Number | Percent | Number | Percent |
| SUR.only | 95 | 10.97 | 133 | 12.69 | 228 | 11.91 |
| RT only | 130 | 15.01 | 125 | 11.93 | 255 | 13.32 |
| Brachytherapy | 4 | 0.46 | 61 | 5.82 | 65 | 3.40 |
| CT only | 29 | 3.35 | 24 | 2.29 | 53 | 2.77 |
| Targeted therapy | 6 | 0.69 | 8 | 0.76 | 14 | 0.73 |
| Hormonal therapy | 7 | 0.81 | 2 | 0.19 | 9 | 0.47 |
| Intervention | 37 | 4.27 | 7 | 0.67 | 44 | 2.30 |
| Nuclear medicine | 5 | 0.58 | 16 | 1.53 | 21 | 1.10 |
| Concurrent chemoradiation | 36 | 4.16 | 18 | 1.72 | 54 | 2.82 |
| Palliative care only | 1 | 0.12 | 1 | 0.10 | 2 | 0.10 |
| SUR.+RT | 18 | 2.08 | 19 | 1.81 | 37 | 1.93 |
| SUR.+Brachytherapy | 0 | 0.00 | 2 | 0.19 | 2 | 0.10 |
| SUR.+CT | 20 | 2.31 | 41 | 3.91 | 61 | 3.19 |
| SUR.+T | 2 | 0.23 | 0 | 0.00 | 2 | 0.10 |
| SUR.+Im | 5 | 0.58 | 3 | 0.29 | 8 | 0.42 |
| SUR.+H | 2 | 0.23 | 27 | 2.58 | 29 | 1.52 |
| SUR.+I | 2 | 0.23 | 0 | 0.00 | 2 | 0.10 |
| SUR.+N | 4 | 0.46 | 15 | 1.43 | 19 | 0.99 |
| SUR.+Concurrent CT-RT | 8 | 0.92 | 7 | 0.67 | 15 | 0.78 |
| SUR.+Concurrent CT-RT+RT | 1 | 0.12 | 0 | 0.00 | 1 | 0.05 |
| SUR.+Concurrent CT-RT+Brachytherapy | 0 | 0.00 | 2 | 0.19 | 2 | 0.10 |
| SUR.+RT+Brachytherapy | 0 | 0.00 | 4 | 0.38 | 4 | 0.21 |
| RT+Brachytherapy | 0 | 0.00 | 11 | 1.05 | 11 | 0.57 |
| RT+Concurrent CT-RT | 2 | 0.23 | 2 | 0.19 | 4 | 0.21 |
| RT+Concurrent CT-RT+Brachytherapy | 0 | 0.00 | 1 | 0.10 | 1 | 0.05 |
| CT+Concurrent CT-RT | 1 | 0.12 | 0 | 0.00 | 1 | 0.05 |
| RT+T | 1 | 0.12 | 1 | 0.10 | 2 | 0.10 |
| RT+CT | 8 | 0.92 | 5 | 0.48 | 13 | 0.68 |
| RT+CT+H | 1 | 0.12 | 2 | 0.19 | 3 | 0.16 |
| RT+CT+T | 1 | 0.12 | 0 | 0.00 | 1 | 0.05 |
| RT+T+I | 1 | 0.12 | 0 | 0.00 | 1 | 0.05 |
| RT+H | 2 | 0.23 | 8 | 0.76 | 10 | 0.52 |
| RT+H+I | 0 | 0.00 | 1 | 0.10 | 1 | 0.05 |
| RT+I | 0 | 0.00 | 1 | 0.10 | 1 | 0.05 |

8

TYPE OF TREATMENT

TYPE OF PRIMARY MANAGEMENT (ALL PATIENT)

| Management of treatment | Ma | Male | | nale | Total | |
|--------------------------------|--------|---------|--------|---------|--------|---------|
| Management of treatment | Number | Percent | Number | Percent | Number | Percent |
| CT+T | 2 | 0.23 | 0 | 0.00 | 2 | 0.10 |
| CT+H | 0 | 0.00 | 2 | 0.19 | 2 | 0.10 |
| I+T | 3 | 0.35 | 0 | 0.00 | 3 | 0.16 |
| Concurrent CT-RT+Brachytherapy | 0 | 0.00 | 8 | 0.76 | 8 | 0.42 |
| Concurrent CT-RT+CT | 2 | 0.23 | 0 | 0.00 | 2 | 0.10 |
| SUR.+RT+CT | 2 | 0.23 | 25 | 2.39 | 27 | 1.41 |
| SUR.+RT+H | 3 | 0.35 | 17 | 1.62 | 20 | 1.04 |
| SUR.+RT+T | 0 | 0.00 | 2 | 0.19 | 2 | 0.10 |
| SUR.+CT+I | 0 | 0.00 | 2 | 0.19 | 2 | 0.10 |
| SUR.+CT+T | 0 | 0.00 | 1 | 0.10 | 1 | 0.05 |
| SUR.+CT+H | 1 | 0.12 | 3 | 0.29 | 4 | 0.21 |
| SUR.+T+I | 1 | 0.12 | 0 | 0.00 | 1 | 0.05 |
| SUR.+N+H | 0 | 0.00 | 1 | 0.10 | 1 | 0.05 |
| SUR.+RT+CT+B | 0 | 0.00 | 2 | 0.19 | 2 | 0.10 |
| SUR.+RT+CT+T | 0 | 0.00 | 1 | 0.10 | 1 | 0.05 |
| SUR.+RT+CT+H | 0 | 0.00 | 3 | 0.29 | 3 | 0.16 |
| Investigation | 106 | 12.24 | 86 | 8.21 | 192 | 10.03 |
| Supportive | 5 | 0.58 | 3 | 0.29 | 8 | 0.42 |
| PET/CT | 87 | 10.05 | 80 | 7.63 | 167 | 8.73 |
| Bone scan | 65 | 7.51 | 60 | 5.73 | 125 | 6.53 |
| Follow-up | 1 | 0.12 | 5 | 0.48 | 6 | 0.31 |
| 2 nd Opinion | 158 | 18.24 | 197 | 18.80 | 355 | 18.55 |
| TBS scan | 1 | 0.12 | 3 | 0.29 | 4 | 0.21 |
| Total | 866 | 100.00 | 1,048 | 100.00 | 1,914 | 100.00 |

SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy

H (Hormone) = Hormonal therapy

T = Targeted therapy

I = Intervention

lm = Immunotherapy


| | | •. | | | TBS scar |
|---|----------------------|------------|-----|------------------|--------------------|
| 19% | | | 0 | | 0% |
| Follow-up | ·····. | 0 | | | |
| 0% | | | | 0 | Surgery |
| Bone scan | | ···· o | | Û. | 24 % |
| 7% | | 0 | | | |
| PET/CT | | | | | |
| 9 % | | · 0 | | 0 | Radiatior |
| | | | | | 15 % |
| Supportive | | | 0 | | Brachytherapy |
| | | | | | 3% |
| Investigation | n | | | Targeted therapy | |
| 10% | Palliative care only | <u>y</u> / | | 2 % | Nuclear mecidine |
| | 0% | | | <u></u> | 1% |
| Concurrent | chemoradiation | | | Chemotherapy | ∎ /0 |
| 4 % | Intervention | | | 4% | Hormonal therapy |
| | ••••• | | • • | | |
| | 3% | | | | 1% |
| | 3 % | | | | 1% |
| PATIEI | 3% NT FOLLOW | UP | | | 1% |
| PATIEI | | UP | | | 1% |
| 2 nd Opinion | NT FOLLOW | UP | | | 1% |
| 2 nd Opinion (No Follow-1 | NT FOLLOW | UP | | 0 | 1% |
| 2 nd Opinion | NT FOLLOW | ' UP | | 0 | |
| 2 nd Opinion (No Follow-1 | NT FOLLOW | ' UP | | 0 | Alive with disease |
| 2 nd Opinion (No Follow-1 | NT FOLLOW | ' UP | | 0 | Alive with disease |
| 2 nd Opinion (No Follow-1 | NT FOLLOW | ' UP | | 0 | Alive with disease |
| 2 nd Opinion (No Follow-1 | NT FOLLOW | ' UP | | 0 | Alive with disease |
| 2 nd Opinion (No Follow-1 | NT FOLLOW | UP | | 0 | Alive with disease |
| 2 nd Opinion (No Follow-1 40% | NT FOLLOW | UP | | 0 | Alive with disease |

| 19% | | | o | 0% |
|--|----------------------|--------|---------------------------------------|---|
| Follow-up | | · | | |
| 0 % | ······ | | | Surgery |
| | | °• | | ° 24 % |
| Bone scan | 0 | | | |
| 7% | | | | |
| PET/CT | ······o | | | • Radiation |
| 9% | | | | 15% |
| Supportive | | | | Brachytherapy |
| 0% | | | | 3% |
| Investigation | ۲ | | | argeted therapy |
| 10% | Palliative care only | | | 2% Nuclear mecidine |
| | 0% | | | 10/ |
| | chemoradiation | | · · · · · · · · · · · · · · · · · · · | |
| 4% | Intervention | | | 4% |
| | | | : | Hormonal therapy |
| | 3 % | | · | |
| 2 nd Opinion (No Follow-I | NT FOLLOW | UP | | 1% Alive with disease |
| 2 nd Opinion (No Follow-1 40% Loss Follow | NT FOLLOW | UP | | 1% Alive with disease |
| 2 nd Opinion (No Follow-1 40% | NT FOLLOW | UP | | 1% Alive with disease |
| 2 nd Opinion (No Follow-1 40% Loss Follow | NT FOLLOW | UP | | Hormonal therapy 1% Alive with disease 37% |

 2^{nd} Opinion only = Intend not to continue diagnosis or treatment at Bangkok Hospital - Soonvijai


OVERALL CANCER

REFERING HOSPITAL




BGH = Consult from Bangkok general hospital WSH only = WATTANOSOTH HOSPITAL BPH = BANGKOK PATTAYA HOSPITAL BNH = BNH HOSPITAL BKH = BANGKOK RATCHASIMA HOSPITAL BRH = BANGKOK RAYONG HOSPITAL BCH = BANGKOK CHANTHABURI HOSPITAL PYT Group = Payathai hospital Group

PATIENT NATIONALITY




BGH only = Not consult from Bangkok general hospital SVH = SAMITIVEJ SUKHUMVIT HOSPITAL BPK = BANGKOK PHUKET HOSPITAL SSH = SAMITIVEJ SRIRACHA HOSPITAL SNH = SAMITIVEJ SRINAKARIN HOSPITAL BHH = BANGKOK HATYAI HOSPITAL BHN = BANGKOK HUAHIN HOSPITAL Paolo Group = Paolo memorial hospital Group



THE TOP 10 LEADING SITE OF NON-THAI PATIENT

| Code | Drimory oito | Male | | Female | | Total | |
|---------|----------------------------|--------|---------|--------|---------|--------|---------|
| Coue | Primary site | Number | Percent | Number | Percent | Number | Percent |
| C50/D05 | Breast (including in situ) | 0 | 0.00 | 176 | 42.93 | 176 | 20.42 |
| C18-C20 | Colorectal | 56 | 12.39 | 34 | 8.29 | 90 | 10.44 |
| C33-C34 | Lung | 58 | 12.83 | 26 | 6.34 | 84 | 9.74 |
| C61 | Prostate gland | 82 | 18.14 | 0 | 0.00 | 82 | 9.51 |
| C22-C24 | Liver & Hepatobiliary | 62 | 13.72 | 19 | 4.63 | 81 | 9.40 |
| C00-C14 | Head & Neck | 40 | 8.85 | 17 | 4.15 | 57 | 6.61 |
| C73 | Thyroid gland | 8 | 1.77 | 33 | 8.05 | 41 | 4.76 |
| C16 | Stomach | 20 | 4.42 | 7 | 1.71 | 27 | 3.13 |
| C53 | Cervix | 0 | 0.00 | 25 | 6.10 | 25 | 2.90 |
| C44 | Skin | 16 | 3.54 | 8 | 1.95 | 24 | 2.78 |


TOP 10 CANCER OF NON-THAI PATIENT ALL GENDER




OVERALL CANCER

Wattanosoth Cancer Registry 2013

TOP 10 CANCER OF NON-THAI PATIENT IN MALE



TOP 10 CANCER OF NON-THAI PATIENT IN FEMALE



Tumor site C50.0 Nipple C50.1 Central portion of breast C50.2 Upper-inner quadrant of breast C50.3 Lower-inner quadrant of breast C50.4 Upper-outer quadrant of breast C50.5 Lower-outer quadrant of breast Overlapping lesion of breast C50.8 Breast, NOS C50.9 Total

| Pathology R | Report | Number |
|-------------|--|--------|
| M8000/3 | Malignant neoplasm | 104 |
| M8050/3 | Papillary carcinoma, NOS | 5 |
| M8070/3 | Squamous cell carcinoma, NOS | 1 |
| M8140/3 | Adenocarcinoma, NOS | 2 |
| M8211/3 | Tubular carcinoma, NOS | 2 |
| M8480/3 | Mucinous carcinoma | 2 |
| M8500/2 | Ductal carcinoma in situ | 35 |
| M8500/3 | Invasive ductal carcinoma | 267 |
| M8501/2 | Ductal carcinoma in situ, comedo type | 1 |
| M8503/2 | Ductal carcinoma in situ, papillary | 1 |
| M8510/3 | Medullary carcinoma, NOS | 2 |
| M8520/2 | Lobular carcinoma in situ | 1 |
| M8520/3 | Lobular carcinoma | 15 |
| M8522/3 | Invasive ductal and lobular carcinoma | 1 |
| M8523/3 | Invasive duct mixed with other type of carcinoma | 2 |
| M8575/3 | Metaplastic carcinoma, NOS | 1 |
| M9020/3 | Malignant phyllodes tumor | 2 |
| Total | | 444 |

BREAST CANCER : PATHOLOGY


BREAST CANCER

Wattanosoth Cancer Registry 2013

AGE AND GENDER


| A ma | M | ale | Fer | nale | Total | | |
|-------------|--------|---------|--------|---------|--------|---------|--|
| Age | Number | Percent | Number | Percent | Number | Percent | |
| 00 - 04 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| 05 - 09 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| 10 - 14 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| 15 - 19 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| 20 - 24 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| 25 - 29 | 0 | 0.00 | 2 | 0.45 | 2 | 0.45 | |
| 30 - 34 | 0 | 0.00 | 11 | 2.48 | 11 | 2.48 | |
| 35 - 39 | 0 | 0.00 | 38 | 8.58 | 38 | 8.56 | |
| 40 - 44 | 0 | 0.00 | 55 | 12.42 | 55 | 12.39 | |
| 45 - 49 | 0 | 0.00 | 64 | 14.45 | 64 | 14.41 | |
| 50 - 54 | 0 | 0.00 | 68 | 15.35 | 68 | 15.32 | |
| 55 - 59 | 0 | 0.00 | 59 | 13.32 | 59 | 13.29 | |
| 60 - 64 | 1 | 100.00 | 53 | 11.96 | 54 | 12.16 | |
| 65 - 69 | 0 | 0.00 | 47 | 10.61 | 47 | 10.59 | |
| 70 - 74 | 0 | 0.00 | 22 | 4.97 | 22 | 4.95 | |
| 75 - 79 | 0 | 0.00 | 15 | 3.39 | 15 | 3.38 | |
| 80 - 84 | 0 | 0.00 | 6 | 1.35 | 6 | 1.35 | |
| 85 - 89 | 0 | 0.00 | 2 | 0.45 | 2 | 0.45 | |
| 90 - 94 | 0 | 0.00 | 1 | 0.23 | 1 | 0.23 | |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Total | 1 | 100.00 | 443 | 100.00 | 444 | 100.00 | |

■ Male ■ Female



PATIENT CATEGORY OF BREAST CANCER

| Detiont estadory | Ма | Male | | Female | | tal |
|---|--------|---------|--------|---------|--------|---------|
| Patient category | Number | Percent | Number | Percent | Number | Percent |
| Dx(Here)Rx(Other) | 1 | 100.00 | 35 | 7.90 | 36 | 8.11 |
| Dx(Here)Rx(Here) | 0 | 0.00 | 95 | 21.44 | 95 | 21.40 |
| Dx(Other)Rx(Here) | 0 | 0.00 | 44 | 9.93 | 44 | 9.91 |
| Dx(Other)Rx(Other) 2 nd Opinion only | 0 | 0.00 | 180 | 40.63 | 180 | 40.54 |
| Dx(Other)Rx(Other)Before | 0 | 0.00 | 89 | 20.09 | 89 | 20.05 |
| Total | 1 | 100.00 | 443 | 100.00 | 444 | 100.00 |



Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging) Rx = Treatment


Here = Within Bangkok Hospital - Soonvijai Other = Outside Bangkok Hospital - Soonvijai

METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)

| Mathad of diagnosia | Fer | nale |
|---------------------|--------|---------|
| Method of diagnosis | Number | Percent |
| Biochemical | 0 | 0.00 |
| Other | 13 | 5.70 |
| Cytology | 0 | 0.00 |
| Histology | 215 | 94.30 |
| Imaging | 0 | 0.00 |
| Total | 228 | 100.00 |

Other = Previously diagnosed as Breast cancer from other Hospital but no documentation of diagnosis


STAGING (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)



Unspecified stage = Incomplete staging due to insufficient patient information


TYPE OF TREATMENT (IN BANGKOK HOSPITAL - SOONVIJAI ONLY)

| Management of treatment | | Fei | male | | |
|--|--|--------|---------|-----------------------------|---|
| Ivialia | gement of treatment | Number | Percent | | |
| SUR.only | | 55 | 24.12 | | |
| RT only | | 55 | 24.12 | | |
| CT only | | 4 | 1.75 | | |
| Targeted th | nerapy | 1 | 0.44 | | |
| Hormonal t | herapy | 2 | 0.88 | | |
| Palliative ca | are only | 1 | 0.44 | | |
| SUR.+RT | | 9 | 3.95 | | |
| SUR.+CT | | 14 | 6.14 | | |
| SUR.+H | | 27 | 11.84 | | |
| RT+CT | | 2 | 0.88 | | |
| RT+H | | 8 | 3.51 | | |
| CT+H | | 2 | 0.88 | | |
| RT+CT+H | | 2 | 0.88 | | |
| RT+H+I | | 1 | 0.44 | | |
| SUR+RT+C | СТ | 20 | 8.77 | | |
| SUR+RT+F | | 17 | 7.46 | | |
| SUR.+CT+ | | 1 | 0.44 | | |
| SUR.+CT+ | | 3 | 1.32 | | |
| SUR.+RT+ | | 1 | 0.44 | | |
| SUR.+RT+ | | 3 | 1.32 | | |
| | Total | 228 | 100.00 | | |
| UR.+CT+T | | | | | - |
| % | | ····· | | SUR.+RT+CT+T | 1% |
| % | SUR.+RT+H | | / | SUR.+RT+CT+T | |
| | 7% | 0000 | | | SUR.+RT+CT+ |
| | 7% | 0000 | | | SUR.+RT+CT+ |
| UR.+RT+C | 7% | 0000 | | | SUR.+RT+CT+ |
| UR.+RT+C | 7% RT+H+I | 0 | | | SUR.+RT+CT+ 19 |
| UR.+RT+C | 7% | 0 | | | SUR.+RT+CT+ 19 SUR.on |
| UR.+RT+C)% T+CT+H | 7% RT+H+I 0% | 0 | , 0 | | SUR.+RT+CT+ 19 SUR.on |
| UR.+RT+C <mark>)%</mark> T+CT+H | 7% RT+H+I | 0 | | | SUR.+RT+CT+ 19 SUR.on |
| UR.+RT+C % T+CT+H % | 7% RT+H+I 0% | 0 | | | SUR.+RT+CT+ 19 SUR.on 249 |
| UR.+RT+C % T+CT+H % T+H | 7% RT+H+I 0% CT+H | 0 | | | SUR.+RT+CT+ 19 SUR.on 249 RT on |
| UR.+RT+C % T+CT+H % T+H | 7% RT+H+I 0% CT+H 1% | 0 | | | SUR.+RT+CT+ 1 9 SUR.on 24 9 RT on |
| UR.+RT+C % T+CT+H % T+H % UR.+H | 7% RT+H+I 0% CT+H 1% RT+CT | | 0 | | SUR.+RT+CT+ 19 SUR.on 249 RT on 249 |
|)% UR.+RT+C)% AT+CT+H % AT+H % UR.+H | 7% RT+H+I 0% CT+H 1% RT+CT | 0 | | | SUR.+RT+CT+ 19 SUR.on 249 RT on 249 CT on |
| UR.+RT+C)% T+CT+H % IT+H % UR.+H | 7% RT+H+I 0% CT+H 1% RT+CT 1% | | | 0% argeted therapy Ω% | SUR.+RT+CT+ 19 SUR.on 249 RT on 249 CT on 29 |
| UR.+RT+C)% T+CT+H % T+H % UR.+H | 7% RT+H+I 0% CT+H 1% RT+CT 1% SUR.+CT | | | 0% argeted therapy Ω% | 1% SUR.+RT+CT+ 19 SUR.onl 24% RT onl 24% CT onl 2% Hormonal therap |



CT = Chemotherapy, H (Hormone) = Hormonal therapy T = Targeted therapy

FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)



| Tumor site | | Number |
|------------|-------------------|--------|
| C33.9 | Trachea | 1 |
| C34.1 | Upper lobe, lung | 53 |
| C34.2 | Middle lobe, lung | 4 |
| C34.3 | Lower lobe, lung | 44 |
| C34.9 | Lung, NOS | 119 |
| Total | | 221 |

| Pathology R | eport | Number |
|-------------|--|--------|
| M8000/3 | Malignant neoplasm | 29 |
| M8010/3 | Carcinoma, NOS | 4 |
| M8012/3 | Large cell carcinoma, NOS | 1 |
| M8021/3 | Carcinoma anaplastic, NOS | 1 |
| M8022/3 | Pleomorphic carcinoma | 1 |
| M8041/3 | Small cell carcinoma, NOS | 14 |
| M8046/3 | Non small cell carcinoma | 20 |
| M8070/3 | Squamous cell carcinoma, NOS | 17 |
| M8072/3 | Squamous cell carcinoma, large cell, nonkeratinizing, NOS | 1 |
| M8140/3 | Adenocarcinoma, NOS | 115 |
| M8246/3 | Neuroendocrine carcinoma, NOS | 1 |
| M8250/3 | Bronchiolo-aveolar adenocarcinoma, NOS | 11 |
| M8260/3 | Papillary adenocarcinoma, NOS | 1 |
| M8480/3 | Mucinous adenocarcinoma | 1 |
| M8550/3 | Acinar cell adenocarcinoma | 2 |
| M8560/3 | Adenosquamous carcinoma | 2 |
| Total | | 221 |


LUNG CANCER : PATHOLOGY

LUNG CANCER

AGE AND GENDER


| | Ма | ale | Fen | nale | Total | | |
|---------|--------|---------|--------|---------|--------|---------|--|
| Age | Number | Percent | Number | Percent | Number | Percent | |
| 00 - 04 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| 05 - 09 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| 10 - 14 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| 15 - 19 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| 20 - 24 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| 25 - 29 | 1 | 0.71 | 0 | 0.00 | 1 | 0.45 | |
| 30 - 34 | 1 | 0.71 | 1 | 1.25 | 2 | 0.90 | |
| 35 - 39 | 3 | 2.13 | 3 | 3.75 | 6 | 2.71 | |
| 40 - 44 | 6 | 4.26 | 4 | 5.00 | 10 | 4.52 | |
| 45 - 49 | 5 | 3.55 | 5 | 6.25 | 10 | 4.52 | |
| 50 - 54 | 15 | 10.64 | 8 | 10.00 | 23 | 10.41 | |
| 55 - 59 | 18 | 12.77 | 8 | 10.00 | 26 | 11.76 | |
| 60 - 64 | 23 | 16.31 | 15 | 18.75 | 38 | 17.19 | |
| 65 - 69 | 27 | 19.15 | 12 | 15.00 | 39 | 17.65 | |
| 70 - 74 | 16 | 11.35 | 10 | 12.50 | 26 | 11.76 | |
| 75 - 79 | 16 | 11.35 | 9 | 11.25 | 25 | 11.31 | |
| 80 - 84 | 6 | 4.26 | 2 | 2.50 | 8 | 3.62 | |
| 85 - 89 | 3 | 2.13 | 2 | 2.50 | 5 | 2.26 | |
| 90 - 94 | 1 | 0.71 | 0 | 0.00 | 1 | 0.45 | |
| 95 + | 0 | 0.00 | 1 | 1.25 | 1 | 0.45 | |
| Total | 141 | 100.00 | 80 | 100.00 | 221 | 100.00 | |

■ Male ■ Female



PATIENT CATEGORY OF LUNG CANCER

| Detiont actoriony | Male | | Female | | Total | |
|---|--------|---------|--------|---------|--------|---------|
| Patient category | Number | Percent | Number | Percent | Number | Percent |
| Dx(Here)Rx(Other) | 25 | 17.73 | 12 | 15.00 | 37 | 16.74 |
| Dx(Here)Rx(Here) | 22 | 15.60 | 17 | 21.25 | 39 | 17.65 |
| Dx(Other)Rx(Here) | 37 | 26.24 | 15 | 18.75 | 52 | 23.53 |
| Dx(Other)Rx(Other) 2 nd Opinion only | 37 | 26.24 | 23 | 28.75 | 60 | 27.15 |
| Dx(Other)Rx(Other)Before | 20 | 14.18 | 13 | 16.25 | 33 | 14.93 |
| Total | 141 | 100.00 | 80 | 100.00 | 221 | 100.00 |




Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging) Rx = TreatmentHere = Within Bangkok Hospital - Soonvijai Other = Outside Bangkok Hospital - Soonvijai

METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)

| Mathed of diagnosis | Male | | Female | | Total | |
|---------------------|--------|---------|--------|---------|--------|---------|
| Method of diagnosis | Number | Percent | Number | Percent | Number | Percent |
| Other | 2 | 2.53 | 3 | 6.67 | 5 | 4.03 |
| Cytology | 3 | 3.80 | 1 | 2.22 | 4 | 3.23 |
| Histology | 73 | 92.41 | 41 | 91.11 | 114 | 91.94 |
| Imaging | 1 | 1.27 | 0 | 0.00 | 1 | 0.81 |
| Total | 79 | 100.00 | 45 | 100.00 | 124 | 100.00 |

Other = Previously diagnosed as Lung cancer from other Hospital but no documentation of diagnosis


STAGING (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (IN BANGKOK HOSPITAL - SOONVIJAI ONLY)

| Monogoment of treatment | Ma | Male | | Female | | Total | |
|---------------------------|--------|---------|--------|---------|--------|---------|--|
| Management of treatment | Number | Percent | Number | Percent | Number | Percent | |
| SUR.only | 6 | 7.59 | 5 | 11.11 | 11 | 8.87 | |
| RT only | 40 | 50.63 | 20 | 44.44 | 60 | 48.39 | |
| Brachytherapy | 1 | 1.27 | 0 | 0.00 | 1 | 0.81 | |
| CT only | 11 | 13.92 | 4 | 8.89 | 15 | 12.10 | |
| Targeted therapy | 1 | 1.27 | 6 | 13.33 | 7 | 5.65 | |
| Concurrent chemoradiation | 5 | 6.33 | 1 | 2.22 | 6 | 4.84 | |
| SUR.+RT | 2 | 2.53 | 1 | 2.22 | 3 | 2.42 | |
| SUR.+CT | 2 | 2.53 | 2 | 4.44 | 4 | 3.23 | |
| SUR.+T | 1 | 1.27 | 0 | 0.00 | 1 | 0.81 | |
| RT+Concurrent CT-RT | 1 | 1.27 | 2 | 4.44 | 3 | 2.42 | |
| RT+T | 1 | 1.27 | 1 | 2.22 | 2 | 1.61 | |
| RT+CT | 5 | 6.33 | 2 | 4.44 | 7 | 5.65 | |
| RT+CT+T | 1 | 1.27 | 0 | 0.00 | 1 | 0.81 | |
| CT+T | 2 | 2.53 | 0 | 0.00 | 2 | 1.60 | |
| SUR.+RT+CT | 0 | 0.00 | 1 | 2.22 | 1 | 0.81 | |
| Total | 79 | 100.00 | 45 | 100.00 | 124 | 10.00 | |




SUR. = Surgery RT = External radiation therapy CT = Chemotherapy T = Targeted therapy

| SUR.+RT+CT |
|---------------|
| 1% |
| SUR.only |
| 9% RT only |
| 48% |
| Brachytherapy |
| 1% |
| CT only |
| 12% |

FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)

COLORECTAL CANCER : PATHOLOGY



| C18.0 | Cecum colon |
|-------|--------------------------|
| C18.2 | Ascending colon |
| C18.3 | Hepatic flexure of colon |
| C18.4 | Transverse colon |
| C18.5 | Splenic flexure of colon |
| C18.6 | Descending colon |
| C18.7 | Sigmoid colon |
| C18.9 | Colon, NOS |
| C19.9 | Rectosigmoid colon |
| C20.9 | Rectum |
| Total | |


| Tumor site | | Number |
|-------------|--------------------------------------|--------|
| C18.0 | Cecum colon | 9 |
| C18.2 | Ascending colon | 10 |
| C18.3 | Hepatic flexure of colon | 5 |
| C18.4 | Transverse colon | 6 |
| C18.5 | Splenic flexure of colon | 1 |
| C18.6 | Descending colon | 5 |
| C18.7 | Sigmoid colon | 40 |
| C18.9 | Colon, NOS | 40 |
| C19.9 | Rectosigmoid colon | 19 |
| C20.9 | Rectum | 73 |
| Total | | 208 |
| | | |
| Pathology F | Report | Number |
| M8000/3 | Malignant neoplasm | 55 |
| M8140/3 | Adenocarcinoma | 133 |
| M8240/3 | Carcinoid tumor, NOS | 1 |
| M8246/3 | Neuroendocrine carcinoma, NOS | 1 |
| M8480/3 | Mucinous adenocarcinoma | 10 |
| M8481/3 | Mucin producing adenocarcinoma | 2 |
| M8490/3 | Adenocarcinoma signet ring cell type | 6 |
| Total | | 208 |
| | | |

COLORECTAL CANCER

AGE AND GENDER


| A # 0 | Ma | ale | Fer | nale | То | tal |
|--------------|--------|---------|--------|---------|--------|---------|
| Age | Number | Percent | Number | Percent | Number | Percent |
| 00 - 04 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 05 - 09 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 10 - 14 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 15 - 19 | 0 | 0.00 | 1 | 1.06 | 1 | 0.48 |
| 20 - 24 | 1 | 0.88 | 0 | 0.00 | 1 | 0.48 |
| 25 - 29 | 1 | 0.88 | 1 | 1.06 | 2 | 0.96 |
| 30 - 34 | 1 | 0.88 | 1 | 1.06 | 2 | 0.96 |
| 35 - 39 | 1 | 0.88 | 1 | 1.06 | 2 | 0.96 |
| 40 - 44 | 5 | 4.39 | 4 | 4.26 | 9 | 4.33 |
| 45 - 49 | 14 | 12.28 | 9 | 9.57 | 23 | 11.06 |
| 50 - 54 | 15 | 13.16 | 10 | 10.64 | 25 | 12.02 |
| 55 - 59 | 18 | 15.79 | 5 | 5.32 | 23 | 11.06 |
| 60 - 64 | 10 | 8.77 | 15 | 15.96 | 25 | 12.02 |
| 65 - 69 | 15 | 13.16 | 17 | 18.09 | 32 | 15.38 |
| 70 - 74 | 13 | 11.40 | 12 | 12.77 | 25 | 12.02 |
| 75 - 79 | 9 | 7.89 | 9 | 9.57 | 18 | 8.65 |
| 80 - 84 | 7 | 6.14 | 5 | 5.32 | 12 | 5.77 |
| 85 - 89 | 4 | 3.51 | 4 | 4.26 | 8 | 3.85 |
| 90 - 94 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 114 | 100.00 | 94 | 100.00 | 208 | 100.00 |

■ Male ■ Female



PATIENT CATEGORY OF COLORECTAL CANCER

| Potient esterery | Ма | ale | Fen | nale | То | tal |
|---|--------|---------|--------|---------|--------|---------|
| Patient category | Number | Percent | Number | Percent | Number | Percent |
| Dx(Here)Rx(Other) | 14 | 12.28 | 7 | 7.45 | 21 | 10.10 |
| Dx(Here)Rx(Here) | 23 | 20.18 | 25 | 26.60 | 48 | 23.08 |
| Dx(Other)Rx(Here) | 13 | 11.40 | 7 | 7.45 | 20 | 9.62 |
| Dx(Other)Rx(Other) 2 nd Opinion only | 47 | 41.23 | 42 | 44.68 | 89 | 42.79 |
| Dx(Other)Rx(Other)Before | 17 | 14.91 | 13 | 13.83 | 30 | 14.42 |
| Total | 114 | 100.00 | 94 | 100.00 | 208 | 100.00 |




Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging) Rx = Treatment Here = Within Bangkok Hospital - Soonvijai Other = Outside Bangkok Hospital - Soonvijai

METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)

| Mathed of diagnosis | Ma | ale | Fen | nale | То | tal |
|---------------------|--------|---------|--------|---------|--------|---------|
| Method of diagnosis | Number | Percent | Number | Percent | Number | Percent |
| Biochemical | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Other | 2 | 3.77 | 1 | 2.22 | 3 | 3.06 |
| Cytology | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Histology | 51 | 96.23 | 44 | 97.78 | 95 | 96.94 |
| Imaging | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 53 | 100.00 | 45 | 100.00 | 98 | 100.00 |

Other = Previously diagnosed as Colorectal cancer from other Hospital but no documentation of diagnosis


STAGING (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)



Unspecified stage = Incomplete staging due to insufficient patient information


TYPE OF TREATMENT (IN BANGKOK HOSPITAL - SOONVIJAI ONLY)

| Management of treatment | Ma | ale | Female | | Total | |
|---------------------------|--------|---------|--------|---------|--------|---------|
| Management of treatment | Number | Percent | Number | Percent | Number | Percent |
| SUR.only | 15 | 28.30 | 16 | 35.56 | 31 | 31.63 |
| RT only | 13 | 24.53 | 9 | 20.00 | 21 | 21.43 |
| CT only | 4 | 7.55 | 3 | 6.67 | 7 | 7.14 |
| Intervention | 1 | 1.89 | 0 | 0.00 | 1 | 1.02 |
| Concurrent chemoradiation | 6 | 11.32 | 2 | 4.44 | 8 | 8.16 |
| SUR.+CT | 12 | 22.64 | 10 | 22.22 | 22 | 22.45 |
| SUR.+Concurrent CT-RT | 1 | 1.89 | 2 | 4.44 | 3 | 3.06 |
| CT+Concurrent CT-RT | 1 | 1.89 | 0 | 0.00 | 1 | 1.02 |
| SUR.+RT+CT | 0 | 0.00 | 1 | 2.22 | 1 | 1.02 |
| SUR.+CT+I | 0 | 0.00 | 2 | 4.44 | 3 | 3.06 |
| Total | 53 | 100.00 | 45 | 100.00 | 98 | 100.00 |



SUR. = Surgery RT = External radiation therapy CT = Chemotherapy T = Targeted therapy **COLORECTAL CANCER**

FOLLOW UP STATUS (PATIENT TREAMENT IN BANGKOK HOSPITAL - SOONVIJAI)



PROSTATE GLAND CANCER : PATHOLOGY


| 140 |
|-----|
| 140 |
| |

| Patho | OUV | Rei | nori |
|--------|-----------|-----|------|
| i unio | 19 | | |


| Pathology Report | | Number |
|------------------|-----------------------|--------|
| M8000/3 | Malignant neoplasm | 50 |
| M8140/3 | Adenocarcinoma, NOS | 41 |
| M8550/3 | Acinar adenocarcinoma | 49 |
| Total | | 140 |

PATIENT CATEGORY OF PROSTATE GLAND CANCER

| Arro | Ма | ale |
|---------|--------|---------|
| Age | Number | Percent |
| 00 - 04 | 0 | 0.00 |
| 05 - 09 | 0 | 0.00 |
| 10 - 14 | 0 | 0.00 |
| 15 - 19 | 0 | 0.00 |
| 20 - 24 | 0 | 0.00 |
| 25 - 29 | 0 | 0.00 |
| 30 - 34 | 0 | 0.00 |
| 35 - 39 | 0 | 0.00 |
| 40 - 44 | 1 | 0.71 |
| 45 - 49 | 1 | 0.71 |
| 50 - 54 | 2 | 1.43 |
| 55 - 59 | 10 | 7.14 |
| 60 - 64 | 28 | 20.00 |
| 65 - 69 | 36 | 25.71 |
| 70 - 74 | 28 | 20.00 |
| 75 - 79 | 20 | 14.29 |
| 80 - 84 | 7 | 5.00 |
| 85 - 89 | 4 | 2.86 |
| 90 - 94 | 2 | 1.43 |
| 95 + | 1 | 0.71 |
| Total | 140 | 100.00 |



Patient category Dx(Here)Rx(Other) Dx(Here)Rx(Here) Dx(Other)Rx(Here) Dx(Other)Rx(Other) 2nd Opinion on Dx(Other)Rx(Other)Before Total



Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging) Rx = TreatmentHere = Within Bangkok Hospital - Soonvijai

Other = Outside Bangkok Hospital - Soonvijai


| | Male | | |
|----|--------|---------|--|
| | Number | Percent | |
| | 17 | 12.14 | |
| | 29 | 20.71 | |
| | 8 | 5.71 | |
| ly | 70 | 50.00 | |
| | 16 | 11.43 | |
| | 140 | 100.00 | |

METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)

| Mothed of diagnosis | Male | | |
|---------------------|--------|---------|--|
| Method of diagnosis | Number | Percent | |
| Other | 6 | 11.32 | |
| Histology | 46 | 86.79 | |
| Imaging | 1 | 1.89 | |
| Total | 53 | 100.00 | |

Other = Previously diagnosed as Head and Neck cancer from other Hospital but no document of Pathology

STAGING (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)




Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (IN BANGKOK HOSPITAL - SOONVIJAI ONLY)

Management of treatment


| SUR.only | |
|------------------|--|
| RT only | |
| Brachytherapy | |
| Hormonal therapy | |
| SUR.+RT | |
| SUR.+CT | |
| SUR.+H | |
| RT+CT+H | |
| RT+CT | |
| RT+H | |
| SUR.+RT+H | |
| SUR.+CT+H | |
| Total | |



SUR. = Surgery RT = External radiation therapy CT = Chemotherapy T = Targeted therapy

| t | Male | | | |
|---|--------|---------|--|--|
| ι | Number | Percent | | |
| | 12 | 22.64 | | |
| | 16 | 30.19 | | |
| | 3 | 5.66 | | |
| | 7 | 13.21 | | |
| | 4 | 7.55 | | |
| | 1 | 1.89 | | |
| | 1 | 1.89 | | |
| | 1 | 1.89 | | |
| | 2 | 3.77 | | |
| | 2 | 3.77 | | |
| | 3 | 5.66 | | |
| | 1 | 1.89 | | |
| | 53 | 100.00 | | |
| | | | | |

FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)



HEPATOBILIARY CANCER : PATHOLOGY

| Tumor site | | Number |
|------------|------------------------------|--------|
| C22.0 | Liver | 111 |
| C22.1 | Liver (Pathology is M8160/3) | 11 |
| C23.9 | Gall bladder | 8 |
| C24.1 | Ampullar of vater | 7 |
| Total | | 137 |


| Pathology R | leport | Number |
|-------------|-------------------------------|--------|
| M8000/3 | Malignant neoplasm | 88 |
| M8140/3 | Adenocarcinoma, NOS | 7 |
| M8160/3 | Cholangiocarcinoma | 7 |
| M8162/3 | Klatskin tumor | 1 |
| M8170/3 | Hepatocellular carcinoma, NOS | 30 |
| M8246/3 | Neuroendocrine carcinoma, NOS | 1 |
| M8260/3 | Papillary adenocarcinoma | 2 |
| M8560/3 | Adenosquamous carcinoma | 1 |
| Total | | 137 |

| Number | • |
|--------|---|
|--------|---|

HEPATOBILIARY CANCER


Wattanosoth Cancer Registry 2013

PATHOLOGY REPORT OF HEPATOBILIARY CANCER



Malignant neoplasm = Dx For Cancer but unknow special type


| Ago | Ma | ale | Fem | nale | То | tal |
|---------|--------|---------|--------|---------|--------|---------|
| Age | Number | Percent | Number | Percent | Number | Percent |
| 00 - 04 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 05 - 09 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 10 - 14 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 15 - 19 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 20 - 24 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 25 - 29 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 30 - 34 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 35 - 39 | 3 | 2.91 | 1 | 2.94 | 4 | 2.92 |
| 40 - 44 | 2 | 1.94 | 0 | 0.00 | 2 | 1.46 |
| 45 - 49 | 9 | 8.74 | 3 | 8.82 | 12 | 8.76 |
| 50 - 54 | 18 | 17.48 | 3 | 8.82 | 21 | 15.33 |
| 55 - 59 | 13 | 12.62 | 6 | 17.65 | 19 | 13.87 |
| 60 - 64 | 17 | 16.50 | 7 | 20.59 | 24 | 17.52 |
| 65 - 69 | 16 | 15.53 | 5 | 14.71 | 21 | 15.33 |
| 70 - 74 | 10 | 9.71 | 3 | 8.82 | 13 | 9.49 |
| 75 - 79 | 12 | 11.65 | 2 | 5.88 | 14 | 10.22 |
| 80 - 84 | 3 | 2.91 | 2 | 5.88 | 5 | 3.65 |
| 85 - 89 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 90 - 94 | 0 | 0.00 | 2 | 5.88 | 2 | 1.46 |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 103 | 100.00 | 34 | 100.00 | 137 | 100.00 |



AGE AND GENDER

PATIENT CATEGORY OF LIVER & HEPATOBILIARY

| Dationt astagory | Ma | Male | | Female | | tal |
|---|--------|---------|--------|---------|--------|---------|
| Patient category | Number | Percent | Number | Percent | Number | Percent |
| Dx(Here)Rx(Other) | 18 | 17.48 | 4 | 11.76 | 22 | 16.06 |
| Dx(Here)Rx(Here) | 34 | 33.01 | 11 | 32.35 | 45 | 32.85 |
| Dx(Other)Rx(Here) | 18 | 17.48 | 5 | 14.71 | 23 | 16.79 |
| Dx(Other)Rx(Other) 2 nd Opinion only | 28 | 27.18 | 11 | 32.35 | 39 | 28.47 |
| Dx(Other)Rx(Other)Before | 5 | 4.85 | 3 | 8.82 | 8 | 5.84 |
| Total | 103 | 100.00 | 34 | 100.00 | 137 | 100.00 |





56%

Imaging **46**%

Dx(Here)Rx(Here)


33%

Imaging

Dx(Other)Rx(Here) 17% Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging) Rx = TreatmentHere = Within Bangkok Hospital - Soonvijai


Other = Outside Bangkok Hospital - Soonvijai


METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)



STAGING (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)


TYPE OF TREATMENT (IN BANGKOK HOSPITAL - SOONVIJAI ONLY)





Unspecified stage = Incomplete staging due to insufficient patient information

| Management of treatment | Ma | ale | Fen | nale | То | tal |
|-------------------------|--------|---------|--------|---------|--------|---------|
| Management of treatment | Number | Percent | Number | Percent | Number | Percent |
| SUR.only | 6 | 10.53 | 5 | 26.32 | 11 | 14.47 |
| RT only | 1 | 1.75 | 1 | 5.26 | 2 | 2.63 |
| CT only | 1 | 1.75 | 1 | 5.26 | 2 | 2.63 |
| Targeted therapy | 3 | 5.26 | 0 | 0.00 | 3 | 3.95 |
| Intervention | 36 | 63.16 | 7 | 36.84 | 43 | 56.58 |
| SUR.+CT | 1 | 1.75 | 3 | 15.79 | 4 | 5.26 |
| SUR.+I | 2 | 3.51 | 0 | 0.00 | 2 | 2.63 |
| SUR.+Concurrent CT-RT | 1 | 1.75 | 1 | 5.26 | 2 | 2.63 |
| RT+T+I | 1 | 1.75 | 0 | 0.00 | 1 | 1.32 |
| RT+CT | 1 | 1.75 | 0 | 0.00 | 1 | 1.32 |
| RT+I | 0 | 0.00 | 1 | 5.26 | 1 | 1.32 |
| I+T | 3 | 5.26 | 0 | 0.00 | 3 | 3.95 |
| SUR.+T+I | 1 | 1.75 | 0 | 0.00 | 1 | 1.32 |
| Total | 57 | 100.00 | 19 | 100.00 | 76 | 100.00 |




SUR. = Surgery RT = External radiation therapy CT = Chemotherapy I = Intervention

HEPATOBILIARY CANCER

TYPE OF TREATMENT IN HEPATOMA CANCER (IN BANGKOK HOSPITAL - SOONVIJAI ONLY)


| Management of treatment | Ма | ale | Female | | Total | |
|-------------------------|--------|---------|--------|---------|--------|---------|
| Management of treatment | Number | Percent | Number | Percent | Number | Percent |
| SUR.only | 3 | 6.12 | 2 | 20.00 | 5 | 8.47 |
| RT only | 1 | 2.04 | 1 | 10.00 | 2 | 3.39 |
| Targeted therapy | 3 | 6.12 | 0 | 0.00 | 3 | 5.08 |
| Intervention | 35 | 71.43 | 7 | 70.00 | 42 | 71.19 |
| SUR.+I | 2 | 4.08 | 0 | 0.00 | 2 | 3.39 |
| I+T | 3 | 6.12 | 0 | 0.00 | 3 | 5.08 |
| SUR.+T+I | 1 | 2.04 | 0 | 0.00 | 1 | 1.69 |
| RT+T+I | 1 | 2.04 | 0 | 0.00 | 1 | 1.69 |
| Total | 49 | 100.00 | 10 | 100.00 | 59 | 100.00 |



Dead with disease 5% Alive without disease 30%

Dead with disease 7% Alive without disease 26%


FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)



HEMATOLOGIC MALIGNANCIES 2013 DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES


| Code | Disease | Ма | Male | | Female | | tal |
|------|---|--------|---------|--------|---------|--------|---------|
| Coue | Disease | Number | Percent | Number | Percent | Number | Percent |
| C81 | Hodgkin's disease | 9 | 10.98 | 4 | 8.70 | 13 | 10.16 |
| C82 | Follicular NHL | 5 | 6.10 | 5 | 10.87 | 10 | 7.81 |
| C83 | Diffuse NHL | 30 | 36.59 | 15 | 32.61 | 45 | 35.16 |
| C84 | Peripheral and cutaneous T-cell lymphoma | 4 | 4.88 | 3 | 6.52 | 7 | 5.47 |
| C85 | Other and unspecified type of NHL | 5 | 6.10 | 5 | 10.87 | 10 | 7.81 |
| C90 | Multiple myeloma | 6 | 7.32 | 1 | 2.17 | 7 | 5.47 |
| C91 | Lymphoid leukemia | 10 | 12.20 | 2 | 4.35 | 12 | 9.38 |
| C92 | Myeloid leukemia | 13 | 15.85 | 11 | 23.91 | 24 | 18.75 |
| | Total | 82 | 100.00 | 46 | 100.00 | 128 | 100.00 |

All patient




DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY AGE AND GENDER

| Ago | Ма | ale | Fen | nale | То | tal |
|---------|--------|---------|--------|---------|--------|---------|
| Age | Number | Percent | Number | Percent | Number | Percent |
| 00 - 04 | 2 | 2.44 | 0 | 0.00 | 2 | 1.56 |
| 05 - 09 | 1 | 1.22 | 0 | 0.00 | 1 | 0.78 |
| 10 - 14 | 1 | 1.22 | 3 | 6.52 | 4 | 3.13 |
| 15 - 19 | 4 | 4.88 | 2 | 4.35 | 6 | 4.69 |
| 20 - 24 | 3 | 3.66 | 2 | 4.35 | 5 | 3.91 |
| 25 - 29 | 3 | 3.66 | 2 | 4.35 | 5 | 3.91 |
| 30 - 34 | 6 | 7.32 | 1 | 2.17 | 7 | 5.47 |
| 35 - 39 | 5 | 6.10 | 4 | 8.70 | 9 | 7.03 |
| 40 - 44 | 5 | 6.10 | 2 | 4.35 | 7 | 5.47 |
| 45 - 49 | 8 | 9.76 | 3 | 6.52 | 11 | 8.59 |
| 50 - 54 | 5 | 6.10 | 4 | 8.70 | 9 | 7.03 |
| 55 - 59 | 8 | 9.76 | 2 | 4.35 | 10 | 7.81 |
| 60 - 64 | 8 | 9.76 | 6 | 13.04 | 14 | 10.94 |
| 65 - 69 | 11 | 13.41 | 6 | 13.04 | 17 | 13.28 |
| 70 - 74 | 7 | 8.54 | 4 | 8.70 | 11 | 8.59 |
| 75 - 79 | 3 | 3.66 | 1 | 2.17 | 4 | 3.13 |
| 80 - 84 | 2 | 2.44 | 2 | 4.35 | 4 | 3.13 |
| 85 - 89 | 0 | 0.00 | 1 | 2.17 | 1 | 0.78 |
| 90 - 94 | 0 | 0.00 | 1 | 2.17 | 1 | 0.78 |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 82 | 100.00 | 46 | 100.00 | 128 | 100.00 |



OVERALL HEMATOLOGIC MALIGNANCIES

PATIENT CATEGORY



Dx = Diagnosis for cancer

Rx = Treatment


Here = Within Bangkok Hospital - Soonvijai

Other = Outside Bangkok Hospital - Soonvijai

| Patient nationality | Ма | ale | Female | | Total | |
|---------------------|--------|---------|--------|---------|--------|---------|
| | Number | Percent | Number | Percent | Number | Percent |
| Thai | 32 | 39.02 | 25 | 54.35 | 57 | 44.53 |
| Non - Thai | 50 | 60.98 | 21 | 45.65 | 71 | 55.47 |
| Total | 82 | 100.00 | 46 | 100.00 | 128 | 100.00 |

Non - Thai **55%**


PATIENT NATIONALITY




HEMATOLOGIC MALIGNANCIES IN NON-THAI PATIENT

| Code | Disease | Ма | ale | Female | | Total | |
|------|---|--------|---------|--------|---------|--------|---------|
| Coue | Disease | Number | Percent | Number | Percent | Number | Percent |
| C81 | Hodgkin's disease | 3 | 6.00 | 3 | 14.29 | 6 | 8.45 |
| C82 | Follicular NHL | 2 | 4.00 | 1 | 4.76 | 3 | 4.23 |
| C83 | Diffuse NHL | 23 | 46.00 | 7 | 33.33 | 30 | 42.25 |
| C84 | Peripheral and cutaneous T-cell lymphoma | 3 | 6.00 | 2 | 9.52 | 5 | 7.04 |
| C85 | Other and unspecified type of NHL | 0 | 0.00 | 2 | 9.52 | 2 | 2.82 |
| C90 | Multiple myeloma | 4 | 8.00 | 0 | 0.00 | 4 | 5.63 |
| C91 | Lymphoid leukemia | 7 | 14.00 | 1 | 4.76 | 8 | 11.27 |
| C92 | Myeloid leukemia | 8 | 16.00 | 5 | 23.81 | 13 | 18.31 |
| | Total | 50 | 100.00 | 21 | 100.00 | 71 | 100.00 |

Non - Thai patient





PATIENT FOLLOW UP STATUS


LYMPHOMA AGE AND GENDER

| Ago | Ma | ale | Fen | nale | Total | | |
|---------|--------|---------|--------|---------|--------|---------|--|
| Age | Number | Percent | Number | Percent | Number | Percent | |
| 00 - 04 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| 05 - 09 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| 10 - 14 | 0 | 0.00 | 1 | 3.13 | 1 | 1.18 | |
| 15 - 19 | 3 | 5.66 | 2 | 6.25 | 5 | 5.88 | |
| 20 - 24 | 3 | 5.66 | 2 | 6.25 | 5 | 5.88 | |
| 25 - 29 | 1 | 1.89 | 1 | 3.13 | 2 | 2.35 | |
| 30 - 34 | 3 | 5.66 | 1 | 3.13 | 4 | 4.71 | |
| 35 - 39 | 3 | 5.66 | 2 | 6.25 | 5 | 5.88 | |
| 40 - 44 | 4 | 7.55 | 1 | 3.13 | 5 | 5.88 | |
| 45 - 49 | 5 | 9.43 | 1 | 3.13 | 6 | 7.06 | |
| 50 - 54 | 3 | 5.66 | 3 | 9.38 | 6 | 7.06 | |
| 55 - 59 | 6 | 11.32 | 2 | 6.25 | 8 | 9.41 | |
| 60 - 64 | 6 | 11.32 | 6 | 18.75 | 12 | 14.12 | |
| 65 - 69 | 7 | 13.21 | 5 | 15.63 | 12 | 14.12 | |
| 70 - 74 | 6 | 11.32 | 2 | 6.25 | 8 | 9.41 | |
| 75 - 79 | 1 | 1.89 | 0 | 0.00 | 1 | 1.18 | |
| 80 - 84 | 2 | 3.77 | 1 | 3.13 | 3 | 3.53 | |
| 85 - 89 | 0 | 0.00 | 1 | 3.13 | 1 | 1.18 | |
| 90 - 94 | 0 | 0.00 | 1 | 3.13 | 1 | 1.18 | |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Total | 53 | 100.00 | 32 | 100.00 | 85 | 100.00 | |

| | Ma | ale | Fen | nale | Total | | |
|-----------|--------|---------|--------|---------|--------|---------|--|
| Age group | Number | Percent | Number | Percent | Number | Percent | |
| < 15 yr. | 0 | 0.00 | 1 | 3.13 | 1 | 1.18 | |
| ≥ 15 yr. | 53 | 100.00 | 31 | 96.88 | 84 | 98.82 | |
| Total | 53 | 100.00 | 32 | 100.00 | 85 | 100.00 | |

≥ 15 yr. **99**%

Male Female






METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)

| Conclude method of diagnosis | Male | | Female | | Total | |
|---|--------|---------|--------|---------|--------|---------|
| Conclude method of diagnosis | Number | Percent | Number | Percent | Number | Percent |
| Histopathology only | 9 | 39.13 | 7 | 50.00 | 16 | 43.24 |
| Histopathology + Flow cytometry | 8 | 34.78 | 4 | 28.57 | 12 | 32.43 |
| Histopathology + Immunohistochemistry | 2 | 8.70 | 1 | 7.14 | 3 | 8.11 |
| Histopathology + Immunohistochemistry + Chromosome | 1 | 4.35 | 0 | 0.00 | 1 | 2.70 |
| Histopathology + Flow cytometry + Immunohistochemistry | 3 | 13.04 | 1 | 7.14 | 4 | 10.81 |
| Histopathology + Cytology + Immunohistochemistry | 0 | 0.00 | 1 | 7.14 | 1 | 2.70 |
| Total | 23 | 100.00 | 14 | 100.00 | 37 | 100.00 |

STAGING (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)

| Management of treatment | Ма | Male | | Female | | tal |
|--|--------|---------|--------|---------|--------|---------|
| Management of treatment | Number | Percent | Number | Percent | Number | Percent |
| Surgery only | 0 | 0.00 | 1 | 7.14 | 1 | 2.70 |
| Radiationtherapy only | 3 | 13.04 | 5 | 35.71 | 8 | 21.62 |
| Chemotherapy only | 13 | 56.52 | 6 | 42.86 | 19 | 51.35 |
| Phototherapy | 0 | 0.00 | 1 | 7.14 | 1 | 2.70 |
| Surgery + Radiationtherapy | 1 | 4.35 | 0 | 0.00 | 1 | 2.70 |
| Surgery + Chemotherapy | 0 | 0.00 | 1 | 7.14 | 1 | 2.70 |
| Surgery + Radiationtherapy + Chemotherapy | 1 | 4.35 | 0 | 0.00 | 1 | 2.70 |
| Radiationtherapy + Chemotherapy | 4 | 17.39 | 0 | 0.00 | 4 | 10.81 |
| Radiationtherapy + Phototherapy | 1 | 4.35 | 0 | 0.00 | 1 | 2.70 |
| Total | 23 | 100.00 | 14 | 100.00 | 37 | 100.00 |

Radiationtherapy + Phototherapy

3%

Radiationtherapy + Chemotherapy

11%

Surgery + Radiationtherapy + Chemotherapy

3%

Surgery + Chemotherapy


3%

Surgery + Radiationtherapy

3%


Phototherapy

3%




PATIENT FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)

| Follow up status | Ма | Male | | Female | | tal |
|-----------------------|--------|---------|--------|---------|--------|---------|
| Follow up status | Number | Percent | Number | Percent | Number | Percent |
| Alive with disease | 18 | 78.26 | 13 | 92.86 | 31 | 83.78 |
| Alive without disease | 3 | 13.04 | 0 | 0.00 | 3 | 8.11 |
| Dead with disease | 2 | 8.70 | 1 | 7.14 | 3 | 8.11 |
| Total | 23 | 100.00 | 14 | 100.00 | 37 | 100.00 |




| Ago | Ma | ale | Female To | | otal | |
|---------|--------|---------|-----------|---------|--------|---------|
| Age | Number | Percent | Number | Percent | Number | Percent |
| 00 - 04 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 05 - 09 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 10 - 14 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 15 - 19 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 20 - 24 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 25 - 29 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 30 - 34 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 35 - 39 | 1 | 16.67 | 0 | 0.00 | 1 | 14.29 |
| 40 - 44 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 45 - 49 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 50 - 54 | 1 | 16.67 | 0 | 0.00 | 1 | 14.29 |
| 55 - 59 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 60 - 64 | 2 | 33.33 | 0 | 0.00 | 2 | 28.57 |
| 65 - 69 | 1 | 16.67 | 0 | 0.00 | 1 | 14.29 |
| 70 - 74 | 1 | 16.67 | 1 | 100.00 | 2 | 28.57 |
| 75 - 79 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 80 - 84 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 85 - 89 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 90 - 94 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 6 | 100.00 | 1 | 100.00 | 7 | 100.00 |




MULTIPLE MYELOMA AGE AND GENDER




TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)



PATIENT FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)



| | Male | | Fen | nale | Total | |
|-----------|--------|---------|--------|---------|--------|---------|
| Age group | Number | Percent | Number | Percent | Number | Percent |
| < 15 yr. | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| ≥ 15 yr. | 6 | 100.00 | 1 | 100.00 | 7 | 100.00 |
| Total | 6 | 100.00 | 1 | 100.00 | 7 | 100.00 |



METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)

| Conclude method of diagnosis | Female | | | | |
|------------------------------|--------|---------|--|--|--|
| Conclude method of diagnosis | Number | Percent | | | |
| Histopathology only | 1 | 100.00 | | | |
| Total | 1 | 100.00 | | | |

| | Female | | | | | |
|---|--------|---------|--|--|--|--|
| ι | Number | Percent | | | | |
| | 1 | 100.00 | | | | |
| | 1 | 100.00 | | | | |

| Female | | | | | | |
|--------|---------|--|--|--|--|--|
| Number | Percent | | | | | |
| 1 | 100.00 | | | | | |
| 1 | 100.00 | | | | | |


LEUKEMIA AGE AND GENDER


| A = 10 | Ма | ale | Fen | nale | То | tal |
|---------------|--------|---------|--------|---------|--------|---------|
| Age | Number | Percent | Number | Percent | Number | Percent |
| 00 - 04 | 2 | 8.70 | 0 | 0.00 | 2 | 5.56 |
| 05 - 09 | 1 | 4.35 | 0 | 0.00 | 1 | 2.78 |
| 10 - 14 | 1 | 4.35 | 2 | 15.38 | 3 | 8.33 |
| 15 - 19 | 1 | 4.35 | 0 | 0.00 | 1 | 2.78 |
| 20 - 24 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 25 - 29 | 2 | 8.70 | 1 | 7.69 | 3 | 8.33 |
| 30 - 34 | 3 | 13.04 | 0 | 0.00 | 3 | 8.33 |
| 35 - 39 | 1 | 4.35 | 2 | 15.38 | 3 | 8.33 |
| 40 - 44 | 1 | 4.35 | 1 | 7.69 | 2 | 5.56 |
| 45 - 49 | 3 | 13.04 | 2 | 15.38 | 5 | 13.89 |
| 50 - 54 | 1 | 4.35 | 1 | 7.69 | 2 | 5.56 |
| 55 - 59 | 2 | 8.70 | 0 | 0.00 | 2 | 5.56 |
| 60 - 64 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 65 - 69 | 3 | 13.04 | 1 | 7.69 | 4 | 11.11 |
| 70 - 74 | 0 | 0.00 | 1 | 7.69 | 1 | 2.78 |
| 75 - 79 | 2 | 8.70 | 1 | 7.69 | 3 | 8.33 |
| 80 - 84 | 0 | 0.00 | 1 | 7.69 | 1 | 2.78 |
| 85 - 89 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 90 - 94 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 23 | 100.00 | 13 | 100.00 | 36 | 100.00 |

| | Male | | Fen | nale | Total | | |
|-----------|--------|---------|--------|---------|--------|---------|--|
| Age group | Number | Percent | Number | Percent | Number | Percent | |
| < 15 yr. | 4 | 17.39 | 2 | 15.38 | 6 | 16.67 | |
| ≥ 15 yr. | 19 | 82.61 | 11 | 84.62 | 30 | 83.33 | |
| Total | 23 | 100.00 | 13 | 100.00 | 36 | 100.00 | |

≥ 15 yr. **83**%







LEUKEMIA

METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)


| Conclude method of diagnosis | Ма | Male | | Female | | tal |
|---|--------|---------|--------|---------|--------|---------|
| Conclude method of diagnosis | Number | Percent | Number | Percent | Number | Percent |
| Histopathology only | 2 | 25.00 | 0 | 0.00 | 2 | 18.18 |
| Histopathology + Flow cytometry | 4 | 50.00 | 2 | 66.67 | 6 | 54.55 |
| Histopathology + Flow cytometry + Chromosome | 1 | 12.50 | 1 | 33.33 | 2 | 18.18 |
| Histopathology + Flow cytometry + Immunohistochemistry | 1 | 12.50 | 0 | 0.00 | 1 | 9.09 |
| Total | 8 | 100.00 | 3 | 100.00 | 11 | 100.00 |


PATIENT FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)

| Follow up status | Male | | Fen | nale | Total | |
|--------------------|--------|---------|--------|---------|--------|---------|
| Follow up status | Number | Percent | Number | Percent | Number | Percent |
| Alive with disease | 7 | 87.50 | 3 | 100.00 | 10 | 90.91 |
| Dead with disease | 1 | 12.50 | 0 | 0.00 | 1 | 9.09 |
| Total | 8 | 100.00 | 3 | 100.00 | 11 | 100.00 |

TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL - SOONVIJAI)

| Monogoment of treatment | Ма | ale | Fen | nale | То | tal |
|---|--------|---------|--------|---------|--------|---------|
| Management of treatment | Number | Percent | Number | Percent | Number | Percent |
| Chemotherapy only | 8 | 100.00 | 1 | 33.33 | 9 | 81.82 |
| Targeted therapy | 0 | 0.00 | 1 | 33.33 | 1 | 9.09 |
| Chemotherapy + Bone Marrow Transplantation | 0 | 0.00 | 1 | 33.33 | 1 | 9.09 |
| Total | 8 | 100.00 | 3 | 100.00 | 11 | 100.00 |





9%





AGE DISTRIBUTION IN ALL MALE CANCER NUMBER OF CASE (EXCLUDED HEMATOLOGIC MALIGNANCIES)

| Cole Primary site | | | З | י צ | | | <u> </u> | Ş | | | | | <u>S</u> | ß | 2 | 7 5 | S | о УЧ | | I | | |
|---|-----------|---------------------------------------|-------|------------|--------------|---|-----------|--------|--------------|---------------------|-------------------------|---|-------------------------|-------------|----|------------|---|---------------------------|--------------|---|-------------------------|-------|
| Ip <th>Code</th> <th>Primary site</th> <th>8 - 8</th> <th>· 6 · 6</th> <th>2 - <u>4</u></th> <th></th> <th>- 2 29</th> <th>34 - 3</th> <th></th> <th></th> <th></th> <th></th> <th>64</th> <th><u>.</u> 69</th> <th>74</th> <th>- 2 79</th> <th></th> <th>, c, 3 · 88</th> <th>6 - 4</th> <th>5 Tota</th> <th>al</th> <th>%</th> | Code | Primary site | 8 - 8 | · 6 · 6 | 2 - <u>4</u> | | - 2 29 | 34 - 3 | | | | | 64 | <u>.</u> 69 | 74 | - 2 79 | | , c, 3 · 88 | 6 - 4 | 5 Tota | al | % |
| -CO2TongueTongueCCC< | C00 | Lip | 0 | 0 | 0 | •••••• | 0 | 0 | | •••••• | | | | 0 | 0 | 0 | 0 | | | | | 0.00 |
| GumG | C01 - C02 | Tongue | 0 | 0 | 0 | • • • • • • • • • • | 0 | 0 | | •••••• | •••••• | • • • • • • • • • • • • • | •••••• | N | С | 0 | 0 | • • • • • • • • • • | •••••• | • • • • • • • • • • | 4 | .62 |
| Floor of mouth000 | C03 | Gum | 0 | 0 | 0 | •••••• | 0 | 0 | - | •••••• | •••••• | ••••• | ••••• | 0 | 0 | 0 | 0 | • • • • • • • • • • • • • | •••••• | •••••• | •••••• | 0.35 |
| PalateDescription <td>C04</td> <td>Floor of mouth</td> <td>0</td> <td>0</td> <td>0</td> <td>• • • • • • • • • •</td> <td>0</td> <td>0</td> <td>0</td> <td>• • • • • • • • • •</td> <td>• • • • • • • • • • • •</td> <td>• • • • • • • • • • •</td> <td>• • • • • • • • • • •</td> <td>-</td> <td>0</td> <td>0</td> <td>0</td> <td>• • • • • • • • • • •</td> <td>••••••</td> <td>1</td> <td>••••••</td> <td>0.12</td> | C04 | Floor of mouth | 0 | 0 | 0 | • • • • • • • • • • | 0 | 0 | 0 | • • • • • • • • • • | • • • • • • • • • • • • | • • • • • • • • • • • | • • • • • • • • • • • | - | 0 | 0 | 0 | • • • • • • • • • • • | •••••• | 1 | •••••• | 0.12 |
| Other part of mouth000001000< | C05 | Palate | 0 | 0 | 0 | •••••• | 0 | 0 | 0 | •••••• | •••••• | • | ••••• | 0 | 0 | 0 | 0 | • • • • • • • • • • • • • | •••••• | •••••• | 0 | .12 |
| Farotid gland I < | C06 | Other part of mouth | 0 | 0 | 0 | • • • • • • • • • • | 0 | 0 | | •••••• | •••••• | ••••• | •••••• | 0 | - | 0 | 0 | • • • • • • • • • • | •••••• | • | •••••• | 0.69 |
| Salivary glandImage: constraint of the second | C07 | Parotid gland | 0 | 0 | 0 | •••••• | 0 | 0 | 0 | •••••• | •••••• | • • • • • • • • • • • • • | ••••• | - | - | - | 0 | • • • • • • • • • • • • | •••••• | •••••• | •••••• | 0.69 |
| TonsilTons | C08 | Salivary gland | 0 | 0 | 0 | • • • • • • • • • • | 0 | 0 | 0 | •••••• | •••••• | •••••• | •••••• | 0 | 0 | 0 | 0 | • • • • • • • • • • | •••••• | 0 | • • • • • • • • • • | 0.00 |
| Image: constraint of the constrat of the constraint of the constraint of the constraint of the co | C09 | Tonsil | 0 | 0 | 0 | • | 0 | 0 | 0 | •••••• | •••••• | | •••••• | - | N | 0 | N | | | ••••• | | 0.81 |
| -C14 Head & Neck 0 0 0 0 0 0 0 1 3 7 7 4 5 6 3 2 4 1 0 0 Esophagus Stomach 0 0 0 0 0 0 1 1 5 5 4 3 3 0 | C10 | Oropharynx | 0 | 0 | 0 | • • • • • • • • • • • | 0 | 0 | 0 | •••••• | •••••• | •••••• | •••••• | 0 | 0 | 0 | 0 | • • • • • • • • • • • • • | •••••• | •••••• | • • • • • • • • • • • • | 0.12 |
| Esophagus (1) <td>C11 - C14</td> <td>Head & Neck</td> <td>0</td> <td>0</td> <td>0</td> <td>• • • • • • • • • • • • • • • • • • • •</td> <td>0</td> <td>-</td> <td>с</td> <td>••••••</td> <td>••••••</td> <td>• • • • • • • • • • • • •</td> <td>•••••</td> <td>ო</td> <td>N</td> <td>4</td> <td></td> <td>• • • • • • • • • • • •</td> <td>••••••</td> <td>••••••</td> <td>•••••</td> <td>4.97</td> | C11 - C14 | Head & Neck | 0 | 0 | 0 | • | 0 | - | с | •••••• | •••••• | • • • • • • • • • • • • • | ••••• | ო | N | 4 | | • • • • • • • • • • • • | •••••• | •••••• | ••••• | 4.97 |
| Stomach 0 0 0 0 1 2 4 6 6 2 4 1 1 0 </td <td>C15</td> <td>Esophagus</td> <td>0</td> <td>0</td> <td>0</td> <td>• • • • • • • • • • • • •</td> <td>0</td> <td>0</td> <td>0</td> <td>••••••</td> <td>••••••</td> <td>• • • • • • • • • • • •</td> <td>• • • • • • • • • • • •</td> <td>ო</td> <td>ω</td> <td>ო</td> <td>0</td> <td>• • • • • • • • • • • • •</td> <td></td> <td></td> <td>• • • • • • • • • •</td> <td>3.46</td> | C15 | Esophagus | 0 | 0 | 0 | • • • • • • • • • • • • • | 0 | 0 | 0 | •••••• | •••••• | • • • • • • • • • • • • | • • • • • • • • • • • • | ო | ω | ო | 0 | • • • • • • • • • • • • • | | | • • • • • • • • • • | 3.46 |
| Small intestine 0 0 0 0 0 1 1 1 0 0 1 1 0 0 0 0 0 0 -C20Colon & Rectum 0 0 0 1 < | C16 | Stomach | 0 | 0 | 0 | • • • • • • • • • • • • • | 0 | 0 | 0 | ••••• | •••••• | • • • • • • • • • • • • • | ••••• | N | 4 | - | | ••••• | ••••• | •••••• | | 3.12 |
| -C20 Colon & Rectum 0 0 1 1 1 0 5 14 15 13 13 13 13 13 13 13 13 13 13 13 13 13 14 15 13 13 14 15 13 13 14 15 13 17 16 10 | C17 | Small intestine | 0 | 0 | 0 | | 0 | - | - | | | | | - | 0 | 0 | 0 | | | | | .35 |
| Anus Anus O </td <td>C18 - C20</td> <td>Colon & Rectum</td> <td>0</td> <td>0</td> <td>0</td> <td>• • • • • • • • • • • • • • • • • • • •</td> <td>-</td> <td>-</td> <td>0</td> <td></td> <td></td> <td></td> <td>• • • • • • • • • • •</td> <td>15</td> <td>13</td> <td>0</td> <td>2</td> <td></td> <td></td> <td></td> <td></td> <td>3.05</td> | C18 - C20 | Colon & Rectum | 0 | 0 | 0 | • | - | - | 0 | | | | • • • • • • • • • • • | 15 | 13 | 0 | 2 | | | | | 3.05 |
| -C24 Liver & Hepatobiliary 0 0 0 0 1 2 2 9 15 17 16 10 12 3 0 0 0 0 Pancreas 0 0 0 0 0 0 0 1 2 3 3 4 7 3 1 0 | C21 | Anus | 0 | 0 | 0 | | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | | | | | 0.35 |
| Pancreas 0 0 0 0 0 1 2 2 3 4 7 3 1 0< | C22 - C24 | Liver & Hepatobiliary | 0 | 0 | 0 | • • • • • • • • • • • • • | 0 | - | N | | •••••• | | • • • • • • • • • • | 16 | 10 | 12 | ю | | | | | 1.89 |
| Other and ill-defined digestive organ 0 | C25 | Pancreas | 0 | 0 | 0 | • | 0 | 0 | . | •••••• | •••••• | • • • • • • • • • • • | • • • • • • • • • • • | ~ | Ю | - | 0 | • • • • • • • • • • • • • | | | ••••• | 3.00 |
| Nasal cavity 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 <t< td=""><td>C26</td><td>Other and ill-defined digestive organ</td><td>0</td><td>0</td><td>0</td><td></td><td>0</td><td>0</td><td>0</td><td></td><td>••••••</td><td></td><td>• • • • • • • • • •</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td></td><td></td><td></td><td>0.00</td></t<> | C26 | Other and ill-defined digestive organ | 0 | 0 | 0 | | 0 | 0 | 0 | | •••••• | | • • • • • • • • • • | 0 | 0 | 0 | 0 | | | | | 0.00 |
| Accessory sinuses 0 0 0 0 1 0 1 0 | C30 | Nasal cavity | 0 | 0 | 0 | | 0 | 0 | 0 | | | | | 0 | - | 0 | 0 | | | | | 0.46 |
| Larynx 0 <td>C31</td> <td>Accessory sinuses</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td></td> <td></td> <td></td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td></td> <td></td> <td></td> <td>.23</td> | C31 | Accessory sinuses | 0 | 0 | 0 | | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | | | | | .23 |
| -C34 Lung 0 0 0 0 1 1 3 6 5 15 16 16 6 3 1 Thymus 0 0 0 0 0 0 1 1 1 2 27 16 16 6 3 1 Thymus 0 | C32 | Larynx | 0 | 0 | 0 | | 0 | 0 | 0 | | | | | N | ю | - | 0 | | | | | 2.08 |
| Thymus 0 <td>C33 - C34</td> <td>Lung</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td>-</td> <td>-</td> <td>Ю</td> <td></td> <td></td> <td></td> <td></td> <td>27</td> <td>16</td> <td>16</td> <td>9</td> <td></td> <td></td> <td></td> <td></td> <td>16.28</td> | C33 - C34 | Lung | 0 | 0 | 0 | | - | - | Ю | | | | | 27 | 16 | 16 | 9 | | | | | 16.28 |
| Mediastinum 0 0 1 0 1 0 <th< td=""><td>C37</td><td>Thymus</td><td>0</td><td>0</td><td>0</td><td></td><td>0</td><td>0</td><td>0</td><td></td><td></td><td></td><td></td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td></td><td></td><td></td><td>0.12</td></th<> | C37 | Thymus | 0 | 0 | 0 | | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | | | | | 0.12 |
| -C41 Bone 0 0 1 1 1 0 </td <td>C38</td> <td>Mediastinum</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td>0</td> <td>0</td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td></td> <td></td> <td></td> <td>.23</td> | C38 | Mediastinum | 0 | 0 | 0 | | 0 | 0 | - | | | | | 0 | 0 | 0 | 0 | | | | | .23 |
| - C44 Skin 0 0 0 0 0 0 2 0 3 3 5 2 3 3 7 1 0 1 Retroperitonium 0 | C40 - C41 | Bone | 0 | 0 | | | 0 | - | . | •••••• | •••••• | • • • • • • • • • • • • | • • • • • • • • • • • | - | - | 0 | 0 | • • • • • • • • • • • • | | | - | .04 |
| Retroperitonium 0 | C43 - C44 | Skin | 0 | 0 | 0 | | 0 | 0 | N | | | | N | Ю | က | \sim | - | | | | 0 | 3.46 |
| | C48 | Retroperitonium | 0 | 0 | | | 0 | 0 | 0 | | | | - | - | 0 | 0 | 0 | 0 | | 3 | 0 | .35 |

| | Duimour oito | 8 | 05 | 0 | | 0 | 5 30 |) 35 | 40 | 45 | 50 | 55 | 60 | 65 | 70 | 75 8 | 8 | 5 9(|) 95 | LotoT | ò |
|---|--------------------|------|-----------|--------|---|---------------------|------------|---------------------------|------|--------|----|-------|-------------------------|---------------------------|--------|------------|---|---------------------|--------|--------|-----------|
| Primary site | le | - 40 | · • 60 | - 4 | - 2 | - 24 29 | - <u>6</u> | - 39 | - 44 | - 49 | 54 | - 26 | - 64 | - 69 | 74 7 | - 8 - 6 | - 7 - 8 | -6 -6 | + | I Otal | <u></u> % |
| Connective tissue | | 0 | 0 | - - | | 0 | | | 0 | \sim | 0 | - | | | | | 0 | 0 | 0 | 42 | 1.39 |
| Breast | • | 0 | 0 | 0 | •••••• | •••••• | •••••• | | 0 | 0 | 0 | 0 | •••••• | •••••• | •••••• | •••••• | • • • • • • • • • • | •••••• | •••••• | - | 0.12 |
| Vulva | | 0 | 0 | 0 | 0 | ••••• | | • • • • • • • • • • • • • | 0 | 0 | 0 | 0 | 0 | ••••• | 0 | | ••••• | ••••• | | 0 | 0.00 |
| Vagina | | 0 | 0 | 0 | •••••• | •••••• | •••••• | • • • • • • • • • • | 0 | 0 | 0 | 0 | •••••• | •••••• | •••••• | •••••• | • • • • • • • • • • | •••••• | •••••• | 0 | 0.00 |
| Cervix | | 0 | 0 | 0 | • | ••••• | | • • • • • • • • • • • • • | 0 | 0 | 0 | 0 | ••••• | ••••• | ••••• | | • | ••••• | | 0 | 0.00 |
| Corpus uteri | | 0 | 0 | 0 | •••••• | • • • • • • • • • • | •••••• | • • • • • • • • • • | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • | •••••• | •••••• | • • • • • • • • • • | • • • • • • • • • • | •••••• | 0 | 0.00 |
| Uterus | | 0 | 0 | 0 | •••••• | •••••• | ••••• | • • • • • • • • • • • • | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • | ••••• | ••••• | • • • • • • • • • • • • • | •••••• | ••••• | 0 | 0.00 |
| Ovary | | 0 | 0 | 0 | •••••• | • • • • • • • • • • | •••••• | • • • • • • • • • • | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • • | •••••• | •••••• | • • • • • • • • • • • | • • • • • • • • • • | •••••• | 0 | 0.00 |
| Other female genital organs | gans | 0 | 0 | 0 | •••••• | •••••• | ••••• | • • • • • • • • • • • • | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • | ••••• | ••••• | • • • • • • • • • • • • • | •••••• | ••••• | 0 | 0.00 |
| Placenta | | 0 | 0 | 0 | •••••• | •••••• | | •••••• | 0 | 0 | 0 | 0 | •••••• | •••••• | •••••• | •••••• | •••••• | •••••• | | 0 | 0.00 |
| Penis | | 0 | 0 | 0 | | | | • • • • • • • • • • • • • | 0 | 0 | 0 | 0 | •••••• | ••••• | •••••• | •••••• | • • • • • • • • • • • • • | | | 0 | 0.00 |
| Prostate gland | | 0 | 0 | 0 | •••••• | •••••• | •••••• | • • • • • • • • • • • • | - | - | N | 10 | ••••• | •••••• | ~ | | • • • • • • • • • • • • | •••••• | •••••• | 140 | 16.17 |
| Testis | | 0 | 0 | 0 | • | 0 | ••••• | • • • • • • • • • • • • • | n | က | 0 | 0 | ••••• | ••••• | ••••• | ••••• | • | ••••• | ••••• | 15 | 1.73 |
| Other and unspecified male genital organs | ale genital organs | 0 | 0 | 0 | •••••• | | | • • • • • • • • • • • • • | 0 | 0 | 0 | 0 | • • • • • • • • • • • | • • • • • • • • • • • • • | 0 | •••••• | • • • • • • • • • • • • | | | 0 | 0.00 |
| Urinary tract | | 0 | - | 0 | | | | | - | N | N | ო | | | | | | | | 23 | 2.66 |
| Ureter | | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | | | | | | | | 0 | 0.00 |
| Bladder | | 0 | 0 | 0 | | | | | - | 0 | 4 | N | | | | | | | | 36 | 4.16 |
| Urinary organ unspecified | fied | 0 | 0 | 0 | •••••• | | | • • • • • • • • • • • • • | 0 | 0 | 0 | 0 | • • • • • • • • • • • | • • • • • • • • • • • • • | | •••••• | • • • • • • • • • • • • | | | 0 | 0.00 |
| Eye & Adnexa | | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | | | | | | | | 0 | 00.0 |
| Brain | | 0 | 0 | 0 | •••••• | | | • • • • • • • • • • • • • | 0 | 4 | 0 | 4 | • • • • • • • • • • • • | • • • • • • • • • • • • • | | •••••• | • • • • • • • • • • • • | | | 17 | 1.96 |
| Spinal cord & CNS | | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | | | | | | | | 0 | 0.00 |
| Thyroid gland | | 0 | 0 | 0 | 0 | - | - | С | 2 | - | Ю | 0 | •••••• | | | - - | 0 | | 0 | 17 | 1.96 |
| Adrenal gland | | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | | | | | | | | 0 | 0.00 |
| Other & endocrine gland | pr | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | | | 0 | | | | | - | 0.12 |
| Other & ill-defined | | 0 | 0 | 0 | 0 | | | | 0 | 0 | 0 | 0 | | | | | | | | 0 | 0.00 |
| Unknown Primary site | | 0 | 0 | 0 | 0 | | 0 | - | 0 | 0 | N | N | 0 | - | - | 0 | • • • • • • • • • | 0 | 0 | 2 | 0.81 |
| Ductal carcinoma in situ of breast | itu of breast | 0 | 0 | 0 | | | | 0 | 0 | 0 | 0 | 0 | | | | | | | | 0 | 0.00 |
| All ICD Group | | 0 | | N | ო | 4 | 1 13 | 32 | 38 | 68 | 91 | 104 - | 122 1 | 143 1 | 08 8 | 84 3 | 31 1 | 2 4 | | 866 | 100.00 |
| | | | | | | | | | | | | | | | | | | | - | | |

SUMMARY OF ALL CANCERS

AGE DISTRIBUTION IN ALL FEMALE CANCER NUMBER OF CASE (EXCLUDED HEMATOLOGIC MALIGNANCIES)

| Orde Primary sle Orde Primary sle Orde Primary sle Primary sle <th></th> <th></th> <th></th> <th>L</th> <th></th> <th></th> <th>L</th> <th></th> <th>Ļ</th> <th></th> <th></th> <th></th> <th>8</th> <th>Ļ</th> <th>ŝ</th> <th>Ļ</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> | | | | L | | | L | | Ļ | | | | 8 | Ļ | ŝ | Ļ | | | | | | |
|---|-----------|---------------------------------------|---------|------------|-------------------------|--------|---------|----------|--------------|---------------------------|---------------------------|--------|----------|-----------|------|----------|--------------|--------|---|--------|--------------|------------|
| Ippone Ippone< | Code | Primary site | 04 - 00 | - 6 - 6 | 5 • 4 | | cz - 23 | 34 34 | 66 9 - 66 | | | | ٥u 64 | 69 - 0 | 74 / | د، د/ | | | | - | _ | , 0 |
| Q02Tongue cumQ1 </td <td>C00</td> <td>Lip</td> <td>0</td> <td>0</td> <td></td> <td></td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td></td> <td></td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td></td> <td></td> <td>Ö.</td> <td>10</td> | C00 | Lip | 0 | 0 | | | 0 | 0 | 0 | | | | 0 | 0 | 0 | 0 | 0 | | | | Ö. | 10 |
| ButBu | C01 - C02 | Tongue | 0 | 0 | • • • • • • • • • • • | •••••• | 0 | 0 | - | • • • • • • • • • • • | • • • • • • • • • • | •••••• | N | - | ო | N | . | •••••• | • • • • • • • • • • | | ÷ | 43 |
| Floor of mouth00000011100< | C03 | Gum | 0 | 0 | 0 | •••••• | 0 | 0 | 0 | | •••••• | •••••• | 0 | - | - | 0 | 0 | •••••• | | | Ö. | 19 |
| PalateDefinition00 | C04 | Floor of mouth | 0 | 0 | | | 0 | 0 | 0 | | | | 0 | 0 | 0 | - | 0 | | | | Ö | 48 |
| Other part of mouth 0 | C05 | Palate | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | | •••••• | •••••• | 0 | 0 | 0 | 0 | 0 | | | | Ö | 00 |
| Parotid gland 0 10 0< | C06 | Other part of mouth | 0 | 0 | • • • • • • • • • • • • | •••••• | 0 | 0 | 0 | • • • • • • • • • • • • | • • • • • • • • • • | •••••• | 0 | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • • | | Ö. | 10 |
| Salvary gland 0 0 0 0 1 0 1 <th1< th=""> <th1< t<="" td=""><td>C07</td><td>Parotid gland</td><td>0</td><td>0</td><td>••••••</td><td>••••••</td><td>0</td><td>0</td><td>0</td><td>• • • • • • • • • • • • •</td><td>••••••</td><td>••••••</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>••••••</td><td>• • • • • • • • • • • • •</td><td>••••••</td><td>Ö</td><td>00</td></th1<></th1<> | C07 | Parotid gland | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | • • • • • • • • • • • • • | •••••• | •••••• | 0 | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • • • | •••••• | Ö | 00 |
| TonsilTonsi | C08 | Salivary gland | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | • • • • • • • • • • | •••••• | •••••• | 0 | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • | •••••• | Ö. | 10 |
| Circoptarynx Coroptarynx Coroptarynx Coroptarynx C <thc< th=""> <thc< th=""> <thc< th=""> C</thc<></thc<></thc<> | C09 | Tonsil | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | • • • • • • • • • • • • • | ••••• | •••••• | 0 | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • • • | •••••• | Ö. | 10 |
| C14 Head & Neck 0 0 0 0 1 1 1 2 1 0 1 0 Stomatine 0 | C10 | Oropharynx | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | •••••• | • • • • • • • • • • | •••••• | 0 | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • • • | | ö | 00 |
| Esophagus 0 | C11 - C14 | Head & Neck | 0 | 0 | •••••• | •••••• | - | - | - | • • • • • • • • • • • • • | ••••• | •••••• | N | - | 0 | - | 0 | •••••• | • • • • • • • • • • • • • | •••••• | . | 24 |
| StomachC20C10C1 <th< td=""><td>C15</td><td>Esophagus</td><td>0</td><td>0</td><td>• • • • • • • • • •</td><td>••••••</td><td>0</td><td>0</td><td>0</td><td>• • • • • • • • • • • •</td><td>• • • • • • • • • • • • •</td><td>••••••</td><td>0</td><td>-</td><td>0</td><td>N</td><td>0</td><td>••••••</td><td>• • • • • • • • • • • • •</td><td></td><td>0</td><td>29</td></th<> | C15 | Esophagus | 0 | 0 | • • • • • • • • • • | •••••• | 0 | 0 | 0 | • • • • • • • • • • • • | • • • • • • • • • • • • • | •••••• | 0 | - | 0 | N | 0 | •••••• | • • • • • • • • • • • • • | | 0 | 29 |
| Small intestine00 <th0< th="">0000<</th0<> | C16 | Stomach | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | • • • • • • • • • • • • • | ••••• | •••••• | - | - | - | - | N | •••••• | • • • • • • • • • • • • • | •••••• | <u>–</u> | 72 |
| C20 Colon & Rectum 0 0 1 1 2 4 9 10 5 17 12 9 5 4 0 0 2 4 0 10 5 17 12 9 5 4 0 0 2 0 2 0 0 0 0 0 2 2 1 12 3 5 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 | C17 | Small intestine | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | • • • • • • • • • • • • | • • • • • • • • • • • • • | •••••• | 0 | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • • • | | ö | 00 |
| AnusAnusC24Liver & Hepatobiliary000 | C18 - C20 | Colon & Rectum | 0 | 0 | | | - | - | N | | | | 15 | 17 | 12 | o | £ | •••••• | | | 0 | 06 |
| $\mathbb{C}24$ Liver & Hepatobiliary 0 0 0 0 0 1 0 3 5 2 2 2 0 2 | C21 | Anus | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | • • • • • • • • • • • • | • • • • • • • • • • • • | •••••• | 0 | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • • • | | o. | 19 |
| Pancreas000010001221122011< | C22 - C24 | Liver & Hepatobiliary | 0 | 0 | 0 | ••••• | 0 | 0 | - | • • • • • • • • • • • • • | ••••• | ••••• | ~ | 2 | с | N | N | •••••• | • • • • • • • • • • • • | | ю. | 24 |
| | C25 | Pancreas | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | •••••• | •••••• | •••••• | N | - | - | N | N | •••••• | • | | ÷. | 24 |
| Nasal cavity 0 <t< td=""><td>C26</td><td>Other and ill-defined digestive organ</td><td>0</td><td>0</td><td>•••••</td><td>•••••</td><td>0</td><td>0</td><td>0</td><td>• • • • • • • • • • • • •</td><td>•••••</td><td>•••••</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>••••••</td><td>• • • • • • • • • • • •</td><td>•••••</td><td>Ö</td><td>00</td></t<> | C26 | Other and ill-defined digestive organ | 0 | 0 | ••••• | ••••• | 0 | 0 | 0 | • • • • • • • • • • • • • | ••••• | ••••• | 0 | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • • | ••••• | Ö | 00 |
| Accessory sinuses 0 0 0 1 0 | C30 | Nasal cavity | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | • • • • • • • • • • • • | • • • • • • • • • • • • • | •••••• | 0 | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • • • | | ö | 00 |
| Larynx 0 <td>C31</td> <td>Accessory sinuses</td> <td>0</td> <td>0</td> <td></td> <td></td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td></td> <td></td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td></td> <td></td> <td>Ö.</td> <td>19</td> | C31 | Accessory sinuses | 0 | 0 | | | 0 | 0 | 0 | | | | 0 | 0 | 0 | 0 | 0 | | | | Ö. | 19 |
| C34 Lung Thymus 0 0 0 1 3 4 5 8 15 12 10 9 2 2 0 1 80 1 Thymus 0 0 0 0 0 0 0 0 0 0 0 1 80 1 Mediastinum 0 | C32 | Larynx | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | • • • • • • • • • • • • | • • • • • • • • • • • • • | •••••• | 0 | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • • • | | ö | 00 |
| Thymus Thymus - C41 Mediastinum - C41 Mediastinum 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 1 0 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 1 | C33 - C34 | Lung | 0 | 0 | •••••• | •••••• | 0 | - | n | | ••••• | •••••• | 15 | 12 | 10 | 6 | N | •••••• | | •••••• | 7. | 63 |
| Mediastinum 0 <th< td=""><td>C37</td><td>Thymus</td><td>0</td><td>0</td><td>••••••</td><td>••••••</td><td>0</td><td>0</td><td>0</td><td>• • • • • • • • • • • •</td><td>• • • • • • • • • • • • •</td><td>••••••</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>••••••</td><td>• • • • • • • • • • • • •</td><td></td><td>ö</td><td>00</td></th<> | C37 | Thymus | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | • • • • • • • • • • • • | • • • • • • • • • • • • • | •••••• | 0 | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • • • | | ö | 00 |
| - C41 Bone - C41 Bone - C44 Skin | C38 | Mediastinum | 0 | 0 | •••••• | •••••• | 0 | 0 | 0 | • • • • • • • • • • • • • | •••••• | •••••• | 0 | 0 | 0 | 0 | 0 | •••••• | • • • • • • • • • • • • | •••••• | ö | 00 |
| - C44 Skin 0 0 0 1 0 3 0 1 1 2 1 1 1 0 20 1 Retroperitonium 0 | C40 - C41 | Bone | 0 | - | | •••••• | 0 | - | 0 | • • • • • • • • • • • • | • • • • • • • • • • • • • | •••••• | 0 | 0 | 0 | 0 | 0 | | | | Ö. | 19 |
| Retroperitonium 0 | C43 - C44 | Skin | 0 | 0 | | | က | 0 | - | | | | - | က | - | N | - | | | | . | 91 |
| | C48 | Retroperitonium | 0 | 0 | | | 0 | 0 | 0 | | | | 0 | 0 | 0 | 0 | 0 | | | 0 | ō | 00 |

| % | | 1.24 | 38.84 | 0.10 | 0.00 | 8.78 | 4.10 | 0.38 | 3.05 | 00.00 | 0.00 | 00.00 | 0.00 | 00.00 | 00.00 | 1.05 | 0.38 | 1.24 | 0.00 | 00.00 | 0.86 | 0.00 | 6.20 | 0.10 | 0.10 | 0.00 | 0.76 | 3.44 | |
|--------------|----|-------------------|--------|-------|--------|----------------|--------------|--------|--------|-----------------------------|----------|-------|----------------|--------|---|---------------|--------|---------|---------------------------|--------------|-----------|-------------------|---------------|---------------|-------------------------|---------------------|----------------------|------------------------------------|--|
| Total | | 13 | 407 | - | 0 | 92 | 43 | 4 | 32 | 0 | 0 | 0 | 0 | 0 | 0 | ÷ | 4 | 13 | 0 | 0 | 6 | 0 | 65 | - | - | 0 | ω | 36 | |
| 95 - | ÷ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| <u> 6</u> | 94 | 0 | - | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 85 | 8 | 0 | N | 0 | 0 | - | 0 | 0 | \sim | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 8 - 8 | 84 | 0 | 2 | 0 | 0 | N | \sim | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | N | 0 | - | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | - | |
| 75 | 29 | 0 | 15 | 0 | 0 | 4 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | N | 0 | 0 | 0 | 0 | က | 0 | 0 | 0 | 0 | 0 | |
| 2 ' i | 74 | - | 22 | - | 0 | \sim | \succ | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | С | 0 | 0 | 0 | 0 | 0 | |
| 65 | 69 | 0 | 43 | 0 | 0 | 2 | 9 | - | က | 0 | 0 | 0 | 0 | 0 | 0 | N | - | N | 0 | 0 | - | 0 | က | - | 0 | 0 | - | 4 | |
| 09 | 64 | - | 49 | 0 | 0 | œ | \sim | - | \sim | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | N | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | - | 4 | |
| 55 | 59 | N | 53 | 0 | 0 | 13 | 6 | - | 10 | 0 | 0 | 0 | 0 | 0 | 0 | က | - | 0 | 0 | 0 | - | 0 | \sim | 0 | 0 | 0 | - | 9 | |
| 20 | 54 | - | 64 | 0 | 0 | 15 | 2 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | \sim | 0 | ~ | 0 | 0 | 0 | n | 4 | |
| 45 | 49 | - | 58 | 0 | 0 | 44 | 2 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | N | 0 | 0 | - | 0 | 9 | 0 | 0 | 0 | - | 9 | |
| 40 | 44 | - | 51 | 0 | 0 | 1 0 | \sim | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | œ | 0 | 0 | 0 | - | 4 | |
| 35 | 39 | N | 33 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | \sim | 0 | 10 | 0 | 0 | 0 | 0 | ß | |
| 30 | 34 | - | o | 0 | 0 | с | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ß | 0 | 0 | 0 | 0 | N | |
| 25 | 29 | - | N | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ß | 0 | 0 | 0 | 0 | 0 | |
| 20 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | С | 0 | - | 0 | 0 | 0 | |
| 15 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 9 • 3 | 14 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 05 | 60 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 8 - 3 | 04 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Primary site | | Connective tissue | Breast | Vulva | Vagina | Cervix | Corpus uteri | Uterus | Ovary | Other female genital organs | Placenta | Penis | Prostate gland | Testis | Other and unspecified male genital organs | Urinary tract | Ureter | Bladder | Urinary organ unspecified | Eye & Adnexa | Brain | Spinal cord & CNS | Thyroid gland | Adrenal gland | Other & endocrine gland | Other & ill-defined | Unknown primary site | Ductal carcinoma in situ of breast | |
| Code | | C49 | C50 | C51 | C52 | C53 | C54 | C55 | C56 | C57 | C58 | C60 | C61 | C62 | C63 | C64 - C65 | C66 | C67 | C68 | C69 | C70 - C71 | C72 | C73 | C74 | C75 | C76 | C79 | D05 | |

SUMMARY OF ALL CANCERS

A REPORT ON CANCER SURVIVAL IN WATTANOSOTH **CANCER HOSPITAL**

This report on cancer survival is based on an analysis of data of top 3 common cancers (i.e., breast, colorectal and lung cancer) in Wattanosoth Cancer Hospital (WSH). The data has been collected by the hospital tumor registry. The cancer patients were diagnosed during a 12 month period from January 1 to December 31, 2008. All of them received treatment at WSH and were prospectively followed-up up to December 31, 2013 (5 year follow-up period).

Survival rates were estimated by Kaplan-Meier method. The survival rates of subgroups of cancer patients categorized by age (aged \leq 50 and > 50 years old), sex (male and female) and stage of cancer at diagnosis (stage 1 - 4) were analyzed for comparison.

As this report is hospital registry-based cancer survival analysis, the study may have limitations related to endpoint data and sample size. The observed survival rates are estimated by method which cumulative probability of survival is calculated at consecutive one-month intervals after diagnosis. The information used included death from the cancer and other causes; lost to follow-up before observation period ended; and follow-up ends due to observation period ended. Therefore survival estimated may be biased if the proportion of lost to follow-up or other causes of death is high. Survival rate estimated from small numbers of cases can provide misleading results and may have wide confidence intervals. In addition to compare survival rate between different groups, test for statistical significant may be misleading.

127 cases were diagnosed breast cancer during January 1 to December 31, 2008. At the time of diagnosis, 49 (39.8%) of them were at stage 1, 40 (32.5%) at stage 2, 23 (18.7%) at stage 3, and 11 (8.9%) at stage 4. Their average age was 53.1 years old (SD \pm 12.1).56 (44.1%) of them aged \leq 50 years old and 71 (55.9%) aged > 50 years old.

The median follow-up period of these breast cancer patients was 60 months (25th - 75th percentile: 26 - 60 months). During the 5 year follow-up period, 6 of them were dead and 1 were lost to follow-up.

The overall observed survival rate of the breast cancer patients at 5 year follow-up period was 93.4% (95% CI: 85.8 - 97.0) (Fig. 1). The survival seems to have no difference between the age group of > 50 and \leq 50 years old, of which the survival rate was 91.7% (95% CI: 79.1 - 96.8), and 95.3% (95% CI: 82.3 - 98.8) respectively (Fig. 2).

The observed survival of the early stage breast cancers, i.e., stage 1 and 2 was 97.7% (95% CI: 84.6 to 99.7) and 95.6% (95% CI: 72.9 to 99.4) respectively, while the survival of the late stages, i.e., stage 3 and 4 was 80.7% (95% CI: 51.1 to 93.4) and 100% respectively (Fig. 3). The survival rate tends to be lower in the late stage breast cancers.







Figure 1. Overall observed survival rate of the breast cancer patients in WSH during 5 year follow-up period

BREAST CANCER SURVIVAL

COLORECTAL CANCER SURVIVAL










Figure 3. Observed survival rate of the breast cancer patients in WSH during 5 year follow-up period by stage of the cancer at diagnosis (stage 1 - 4)

62 cases were diagnosed colorectal cancer during January 1 to December 31, 2008. At the time of diagnosis, 7 (11.5%) of them were at stage 1, 10 (16.4%) at stage 2, 28 (45.9%) at stage 3, and 16 (26.2%) at stage 4. Their average age was 61.7 years old (SD \pm 13.6). 13 (21.0%) of them aged \leq 50 years old and 49 (79.0%) aged > 50 years old. Among of them, there were 43 (69.3%) males and 19 (30.7%) females.

The median follow-up period of these colorectal cancer patients was 36 months (25th - 75th percentile: 8 - 60 months). During the 5 year follow-up period, 8 of them were dead and 3 were lost to follow-up.

The overall observed survival rate of the colorectal cancer patients at 5 year follow-up period was 83.7% (95% CI: 69.3 - 91.8) (Fig. 1). The survival among the male patients was 81.6% (95% Cl: 62.0 - 91.7) and female was 87.5% (95% CI: 58.6 - 96.7) (Fig 2). The male patients seem to have lower observed survival rate. The survival seems to have no difference between the age group of > 50 and \leq 50 years old, of which the survival rate was 82.0% (95%) Cl: 64.9 - 91.3) and 90.9% (95%Cl: 50.8 - 98.7) respectively (Fig. 3).

The observed survival of early stage colorectal cancers, i.e., stage 1 and 2 was 100.0% and 83.3% (95% CI: 27.3 - 97.5) respectively, while the survival of the late stages, i.e., stage 3 and 4 was 87.1% (95% CI: 65.0 - 95.6) and 33.7% (95% CI: 1.6 - 75.3) respectively (Fig. 4). The observed survival tends to be decreased as the cancer stage advanced. Especially in the stage 4, the survival was substantially decreased.









Figure 1. Overall observed survival rate of the colorectal cancer patients in WSH during 5 year follow-up period














Figure 4. Observed survival rate of the colorectal cancer patients in WSH during 5 year follow-up period by stage of the cancer at diagnosis (stage 1 - 4)

Kaplan-Meier survival estimates by Stage

LUNG CANCER SURVIVAL

76 cases were diagnosed lung cancer during January 1 to December 31, 2008. At the time of diagnosis, 13 (18.1%) of them were at stage 1, 1 (1.4%) at stage 2, 10 (13.9%) at stage 3, and 48 (66.7%) at stage 4. Their average age was 62.3 years old (SD \pm 12.2). 11 (14.5%) of them aged \leq 50 years old and 65 (85.5%) aged > 50 years old. Among of them, there were 49 (64.5%) males and 27 (35.5%) females.

The median follow-up period of these lung cancer patients was 9 months (25th - 75th percentile: 3 - 27). During the 5 year follow-up period, 27 of them were dead and 2 were lost to follow-up.

The observed survival rate of the lung cancer patients at 5 year follow-up period was 37.5% (95% CI: 20.7 - 54.2) (Fig. 1). The survival seems to have no difference between male and female patients, of which the survival rate was 23.7% (95% CI: 6.7 - 46.3) and 52.4% (95% CI: 24.9 - 74.1) respectively (Fig. 2). The survival of patients aged > 50 and ≤ 50 years old was 36.5% (95% CI: 18.9 - 54.4) and 56.1% (95% CI: 19.5 - 81.5) respectively (Fig. 3). The patients aged > 50 years old seem to have lower observed survival rate.

The observed survival rate of early stage lung cancers, i.e., stage 1 and 2 was 100.0% and 100.0% respectively while the survival of late stages, i.e., stage 3 and 4 was 22.5 (95% CI: 1.2 - 60.3) and 10.2% (95% CI: 0.7 - 34.6) respectively (Fig. 4). The observed survival tends to be decreased as the cancer stage advanced.



Kaplan-Meier survival estimate

Figure 1. Overall observed survival rate of the lung cancer patients in WSH during 5 year follow-up period






Figure 2. Observed survival rate of the lung cancer patients in WSH during 5 year follow-up period by gender (male and female)






Figure 3. Observed survival rate of the lung cancer patients in WSH during 5 year follow-up period by age group of \leq 50 and > 50 years old




Figure 4. Observed survival rate of the lung cancer patients in WSH during 5 year follow-up period by stage of the cancer at diagnosis (stage 1 - 4)



Komgrit Tanisaro M.D.

Natthaphum Khanchanaporn M.D.





Saengduan Chindavijak M.D.

Cancer Registry Team

Surachai Sitawarin M.D.



Waraphorn ChomphuPichet PariyarungsiTumor Registered-Officer (WSH)Senior Bussiness Intelligence Manager